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NON - NEUROINVASIVE VIRUSES AND USES 87 % , 88 % , 89 % , 90 % , 91 % 92 % , 93 % , 94 % , 95 % , 96 % , or 
THEREOF 97 % ) sequence identity to a sequence selected , for example , 
SEQ ID NOS : 22-36 . 
CROSS REFERENCE TO RELATED In some embodiments , the virus comprises one or more 
APPLICATIONS 5 mutations in the neuroinvasive ( R2 ) domain . Examples 
include , for example , a variant herpes simplex virus 1 or 2 
The present Application is a national stage filing under 35 particle comprising a mutant UL37 protein , wherein said 
U.S.C. 371 of International Application No. PCT / US2016 / mutant UL37 protein comprises one or more mutations 
020960 , filed Mar. 4 , 2016 , which claims priority to U.S. selected from Q403A , E452A , Q455A , Q511A , or R515A ; 
Provisional Patent Application Ser . No. 62 / 128,613 filed a variant varicella zoster virus particle comprising a mutant 
Mar. 5 , 2015 , both of which are herein incorporated by UL37 protein , wherein said mutant UL37 protein comprises 
reference in their entirety . one or more mutations selected from Q363A , D413A , 
Q416A , Q472A , or R476A ; and a variant pseudorabies virus 
GOVERNMENT SUPPORT 15 particle comprising a mutant UL37 protein , wherein said 
mutant UL37 protein comprises one or more mutations 
This invention was made with government support under selected from Q324A , D362A , R365A , H421A , or H425A . 
R01 A1056346 and OD001996 both of which were awarded In some embodiments , the one or more mutations is two or 
by the National Institutes of Health . The government has more ( e.g. , three , four , or all ) of the mutations . In some 
certain rights in the invention . 20 embodiments , the virus particle exhibits reduced neuro 
invasiveness relative to a virus particle lacking the muta 
REFERENCE TO SEQUENCE LISTING tions . In some embodiments , the virus is avirulent . SUBMITTED VIA EFS - WEB Further embodiments provide a nucleic acid or vector 
encoding the virus particles described herein . This application is being filed electronically via EFS - Web Additional embodiments provide a pharmaceutical com 
and includes an electronically submitted Sequence Listing in position or vaccine composition comprising the virus par 
.txt format . The .txt file contains a sequence listing entitled ticle , nucleic acid , or vector described herein and a phar 
" 2016-03-04_5369-00332_Sequence_Listing.txt " created maceutically acceptable carrier . In some embodiments , the 
on Mar. 4 , 2016 and is 76 kilobytes in size . The Sequence composition further comprises an adjuvant . 
Listing contained in this .txt file is part of the specification 30 Still other embodiments provide a method of inducing an 
and is hereby incorporated by reference herein in its entirety . immune response against a virus , comprising : administering 
the composition described herein to a subject under condi 
FIELD OF THE DISCLOSURE tions such that said subject generates an immune response to 
the virus . In some embodiments , the subject exhibits immu 
Provided herein are compositions and methods for vac- 35 nity to the virus . 
cination and research applications . In particular , provided Yet other embodiments provide the use of the composi 
herein are non - neuroinvasive herpesviruses and alpha her tions described herein to generate an immune response 
pesviruses and uses thereof . against a virus in a subject . 
Certain embodiments provide method of preventing 
BACKGROUND OF THE DISCLOSURE 40 infection by a virus , comprising : administering the compo 
sitions described herein to a subject under conditions such 
Alphaherpesviruses are neuroinvasive pathogens of that the subject generates an immune response to the virus 
humans and livestock . All cause a range of disease mani and is immune to infection by the virus . In some embodi 
festations from mild to severe , establish life - long infections ments , the subject is human or a non - human animal ( e.g. , 
by invading and residing in the nervous system , and once 45 bovine , equine , companion animal , livestock , etc. ) . 
infected there is no cure . In some embodiments , the present disclosure provides the 
Of the three human pathogens , varicella zoster virus use of the compositions described herein to prevent infection 
( VZV ) and herpes simplex virus type 1 ( HSV - 1 ) and type 2 by a virus in a subject . 
( HSV - 2 ) , there is a vaccine only for VZV . The VZV vaccine Still further embodiments provide a method or use of 
is a live - attenuated virus that retains full neuroinvasive 50 treating or preventing cancer , comprising : administering the properties . composition described herein to a subject diagnosed with 
Additional vaccines for alphaherpesviruses are needed , cancer under conditions such that the cancer is reduced or 
preferably utilizing viruses without neuroinvasive proper eliminated . 
ties . Additional embodiments are described herein . 
55 
SUMMARY OF THE DISCLOSURE DESCRIPTION OF THE DRAWINGS 
Provided herein are compositions and methods for vac FIG . 1 shows UL37N structure . ( A ) Linear diagram of 
cination and research applications . In particular , provided UL37 constructs expressed . HS , the Hish - SUMO tag . ( B ) 
herein are non - neuroinvasive herpesviruses and alpha her- 60 Coomassie - stained SDS - polyacrylamide gel showing puri 
pesviruses and uses thereof . fied His6 - SUMO - tagged UL37 contaminated with the His6 
For example , in some embodiments , the present disclo SUMO - tagged UL37N proteolytic cleavage product and 
sure provides a non - neuroinvasive herepsvirus or alphaher purified monodisperse UL37N . ( C ) Crystal structure of a 
pesvirus ( e.g. , HSV - 1 , HSV - 2 , PRV , VZV , BHV , or EHV ) . In UL37N monomer shown in two orientations related by a 
some embodiments , the UL37 protein of the virus has at 65 180 - degree rotation around the vertical axis . ( D ) A close - up 
least 70 % ( e.g. , at least 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , view of residue W477 and its surroundings . ( E ) UL37N 
77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , domains are shown individually . 
25 
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3 4 
FIG . 2 shows that UL37N ( 1 to 496 ) is more stable over proteins VP22 and VP13 / 14 . ( B ) Non - moving particles are 
time than UL37N ( 1 to 476 ) , as measured using circular predominantly associated with envelope and tegument pro 
dichroism on protein aged 1 day , 2 weeks , or 1 month . teins . 
FIG . 3 shows that UL37N is a calcium - dependent dimer FIG . 12 shows modeling of wild - type and the R2 mutant 
in crystals but not in solution . 5 trafficking in neuronal cells ( Top ) Herpesvirus replication 
( A ) Two UL37N monomers in the asymmetric unit . ( B ) A occurs in the nucleus , this requires incoming particles to 
close - up view of the calcium - binding site at the dimer traverse the cytoplasm following entry into the cell . ( Bot 
interface . ( C ) Overlay of size exclusion chromatograms of tom ) R2 mutant virions fuse with the plasma membrane of 
UL37N with or without 0.2 M CaC12 . ( D ) Electrostatic the axon however the released capsids alternate between 
surface potential map of UL37N generated using the 10 motion towards ( retrograde ) and away ( anterograde ) from 
Charmm program . the soma . 
FIG . 4 shows a sequence alignment of 15 UL37 homologs FIG . 13 shows that PRV R2 lacks neuroinvasive proper 
from alphaherpesviruses . The 15 UL37 homologs shown in ties . 
the alignment are PRV_UL37 ( SEQ ID NO : 22 ) , FIG . 14 shows that PRV R2 is avirulent . 
BHV1_UL37 ( SEQ ID NO : 23 ) , EHV4_UL37 ( SEQ ID 15 FIG . 15 shows that PRV R2 is a potent live - attenuated 
NO : 24 ) , Felid_HV1_UL37 ( SEQ ID NO : 25 ) , Cerco_HV9 vaccine . 
UL37 ( SEQ ID NO : 26 ) , VZVD_UL37 ( SEQ ID NO : 27 ) , FIG . 16 shows that the HSV - 1 R2 mutant ( HSV1 
Gallid_HV2_UL37 ( SEQ ID NO : 28 ) , Gallid_HV3_UL37 GS6298 ) is incapable of transmitting into the nervous sys 
( SEQ ID NO : 29 ) , Meleagrid_HV1_UL37 ( SEQ ID NO : tem following replication in the mouse cornea . 
30 ) , Anatid_HV1_UL37 ( SEQ ID NO : 31 ) , 20 FIG . 17 shows protection of mice from lethal PRV 
Macacine_HV1_UL37 ( SEQ ID NO : 32 ) , challenge following vaccination with PRV encoding the R2 
Papiine_HV2_UL37 ( SEQ ID NO : 33 ) , deletion . 
HSV2_HG52_UL37 ( SEQ ID NO : 34 ) , HSV1_17_UL37 
( SEQ ID NO : 35 ) , Saimiriine_HV1_UL37 ( SEQ ID NO : DEFINITIONS 
36 ) . 
FIG . 5 shows residue conservation on the surface of As used herein , the term “ subject ” refers to any animal 
UL37N . ( A ) The UL37N structure is shown in surface ( e.g. , a mammal ) , including , but not limited to , humans , 
representation . ( B ) ETA class conserved and class specific . non - human primates , rodents , and the like , which is to be the 
( C ) Mutated residues in R1 , R2 , R3 , and the calcium - binding recipient of a particular treatment . Typically , the terms 
site ( Ca ) . 30 “ subject ” and “ patient ” are used interchangeably herein in 
FIG . 6 shows a phylogenetic tree from ETA using UL37 reference to a human subject . 
homologs from 15 alphaherpesviruses . As used herein , the term " non - human animals ” refers to 
FIG . 7 shows propagation and spread of PRV encoding all non - human animals including , but not limited to , verte 
mutant forms of UL37 . ( A ) Relative plaque diameters of brates such as rodents , non - human primates , ovines , 
mutant viruses Ca ( PRV - GS5476 ) , R1 ( PRV - GS5321 ) , R2 35 bovines , ruminants , lagomorphs , porcines , caprines , 
( PRV - G55604 ) , and R3 ( PRV - GS5350 ) . ( B ) Single - step equines , canines , felines , ayes , etc. 
growth curves comparing propagation of PRV - GS4284 As used herein , the term " cell culture ” refers to any in 
( UL37 WT ) and PRV - GS5604 ( UL37 R2 mutant ) . ( C ) vitro culture of cells . Included within this term are continu 
Western blot analysis of UL37 protein incorporation into ous cell lines ( e.g. , with an immortal phenotype ) , primary 
WT and R2 mutant extracellular virions . 40 cell cultures , transformed cell lines , finite cell lines ( e.g. , 
FIG . 8 shows that UL37N shares structural similarities non - transformed cells ) , and any other cell population main 
with several subunits of cellular MTCs . ( A ) UL37N is tained in vitro . 
shown side by side with the Tip20 ( PDB accession no . As used herein , the term “ eukaryote ” refers to organisms 
3FHN ) and Dsl 1 ( PDB accession no . 3K8P ) subunits of the distinguishable from “ prokaryotes . ” It is intended that the 
Dsll complex and the Seco ( PDB accession no . 2FJI ) and 45 term encompass all organisms with cells that exhibit the 
Exo70 ( PDB accession no . 2B7M ) subunits of the exocyst usual characteristics of eukaryotes , such as the presence of 
complex , with the Z - score for each alignment displayed . ( B ) a true nucleus bounded by a nuclear membrane , within 
Overlays of regions of Tip20 , Sech , and Dsl 1 that align onto which lie the chromosomes , the presence of membrane 
residues 1 to 136 of UL37N . ( C ) The salt bridge in domain bound organelles , and other characteristics commonly 
II between putative D and E subdomains of UL37N is 50 observed in eukaryotic organisms . Thus , the term includes , 
strictly conserved among but is not limited to such organisms as fungi , protozoa , and 
FIG . 9 shows characterization of the neuroinvasive prop animals ( e.g. , humans ) . 
erties of the R2 mutant . ( A ) The R2 region is essential for As used herein , the term " in vitro ” refers to an artificial 
virulence in a mouse model of infection . ( B ) The R2 region environment and to processes or reactions that occur within 
is essential for retrograde mediated neuroinvasion . ( C ) The 55 an artificial environment . In vitro environments can consist 
R2 region is dispensable for anterograde spread through of , but are not limited to , test tubes and cell culture . The term 
neurons . ( D ) The R2 mutant does not travel retrograde down “ in vivo ” refers to the natural environment ( e.g. , an animal 
axons upon infection . or a cell ) and to processes or reaction that occur within a 
FIG . 10 shows that R2 mutant particles display aberrant natural environment . 
non - processive motion . ( A ) Mutation of the R2 region 60 As used herein , the term “ sample ” is used in its broadest 
significantly increases the severity of stop and reversal sense . In one sense , it is meant to include a specimen or 
events . ( B ) Aberrant motion of R2 mutant particles does not culture obtained from any source , as well as biological and 
result in overall movement towards the soma environmental samples . Biological samples may be obtained 
FIG . 11 shows that motion of R2 particles does not result from animals ( including humans ) and encompass fluids , 
from endocytosis of virions or retention of outer tegument 65 solids , tissues , and gases . Biological samples include blood 
proteins following entry . ( A ) Moving particles are not asso products , such as plasma , serum and the like . Environmental 
ciated with the gD envelope protein or the outer tegument samples include environmental material such as surface 
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matter , soil , water , and industrial samples . Such examples gen ( e.g. , a pathogen ) as well as acquired ( e.g. , memory ) 
are not however to be construed as limiting the sample types responses that are a result of an adaptive immune response ) . 
applicable to the present disclosure . As used herein , the term “ immunity ” refers to protection 
As used herein , the term “ co - administration ” refers to the from disease ( e.g. , preventing or attenuating ( e.g. , suppres 
administration of at least two agent ( s ) ( e.g. , a composition 5 sion ) of a sign , symptom or condition of the disease ) upon 
described herein and a anti - viral agent ) or therapies to a exposure to a microorganism ( e.g. , pathogen ) capable of 
subject . In some embodiments , the co - administration of two causing the disease . Immunity can be innate ( e.g. , non or more agents / therapies is concurrent . In other embodi adaptive ( e.g. , non - acquired ) immune responses that exist in ments , a first agent / therapy is administered prior to a second the absence of a previous exposure to an antigen ) and / or agent / therapy . The appropriate dosage for co - administration 10 acquired ( e.g. , immune responses that are mediated by B and can be readily determined by one skilled in the art . In some 
embodiments , when agents / therapies are co - administered , T cells following a previous exposure to antigen ( e.g. , that exhibit increased specificity and reactivity to the antigen ) ) . the respective agents / therapies are administered at lower 
dosages than appropriate for their administration alone . As used herein , the term “ immunogen ” refers to a mol 
Thus , co - administration is especially desirable in embodi- 15 ecule which stimulates a response from the adaptive immune 
ments where the co - administration of the agents / therapies system , which may include responses drawn from the group 
lowers the requisite dosage of a known potentially harmful comprising an antibody response , a cytotoxic T cell 
( e.g. , toxic ) agent ( s ) . response , a T helper response , and a T cell memory . An 
As used herein , the term “ pharmaceutical composition ” immunogen may stimulate an upregulation of the immune 
refers to the combination of an active agent with a carrier , 20 response with a resultant inflammatory response , or may 
inert or active , making the composition especially suitable result in down regulation or immunosuppression . Thus the 
for diagnostic or therapeutic use in vivo , in vivo or ex vivo . T - cell response may be a regulatory response . An immu 
As used herein , the term " pharmaceutically acceptable nogen also may stimulate a B - cell response and lead to an 
carrier ” refers to any of the standard pharmaceutical carriers , increase in antibody titer . 
such as a phosphate buffered saline solution , water , emul- 25 Where “ amino acid sequence ” is recited herein to refer to 
sions ( e.g. , such as an oil / water or water / oil emulsions ) , and an amino acid sequence of a naturally occurring protein 
various types of wetting agents . The compositions also can molecule , “ amino acid sequence ” and like terms , such as include stabilizers and preservatives . For examples of car “ polypeptide ” or “ protein ” are not meant to limit the amino riers , stabilizers and adjuvants . ( See e.g. , Martin , Reming 
ton's Pharmaceutical Sciences , 15th Ed . , Mack Publ . Co. , 30 associated with the recited protein molecule . 
acid sequence to the complete , native amino acid sequence 
Easton , Pa . [ 1975 ] ) . As used herein , the term “ peptide ” refers to a polymer of As used herein , the term “ immune response ” refers to a two or more amino acids joined via peptide bonds or response by the immune system of a subject . For example , 
immune responses include , but are not limited to , a detect modified peptide bonds . As used herein , the term “ dipep able alteration ( e.g. , increase ) in Toll receptor activation , 35 tides ” refers to a polymer of two amino acids joined via a 
lymphokine ( e.g. , cytokine ( e.g. , Thl or Th2 type cytokines ) peptide or modified peptide bond . 
or chemokine ) expression and / or secretion , macrophage The term “ wild - type ” refers to a gene or gene product that 
activation , dendritic cell activation , T cell activation ( e.g. , has the characteristics of that gene or gene product when 
CD4 + or CD8 + T cells ) , NK cell activation , and / or B cell isolated from a naturally occurring source . A wild - type gene 
activation ( e.g. , antibody generation and / or secretion ) . Addi- 40 is that which is most frequently observed in a population and 
tional examples of immune responses include binding of an is thus arbitrarily designed the " normal " or " wild - type " form 
immunogen ( e.g. , antigen ( e.g. , immunogenic polypeptide ) ) of the gene . In contrast , the terms “ modified ” , “ mutant ” , and 
to an MHC molecule and inducing a cytotoxic T lymphocyte “ variant ” refer to a gene or gene product that displays 
( " CTL " ) response , inducing a B cell response ( e.g. , antibody modifications in sequence and or functional properties ( i.e. , 
production ) , and / or T - helper lymphocyte response , and / or a 45 altered characteristics ) when compared to the wild - type gene 
delayed type hypersensitivity ( DTH ) response against the or gene product . It is noted that naturally - occurring mutants 
antigen from which the immunogenic polypeptide is can be isolated ; these are identified by the fact that they have 
derived , expansion ( e.g. , growth of a population of cells ) of altered characteristics when compared to the wild - type gene 
cells of the immune system ( e.g. , T cells , B cells ( e.g. , of any or gene product . stage of development ( e.g. , plasma cells ) , and increased 50 As used herein , the term “ neuroinvasive ” refers to a processing and presentation of antigen by antigen presenting property of a microoroganism ( e.g. , virus ) to enter the cells . An immune response may be to immunogens that the nervous system of a subject . In some embodiments , neuro subject's immune system recognizes as foreign ( e.g. , non 
self antigens from microorganisms ( e.g. , pathogens ) , or invasive viruses persist in the nervous system for an 
self - antigens recognized as foreign ) . Thus , it is to be under- 55 extended period of time ( e.g. , many years to an entire 
stood that , as used herein , “ immune response ” refers to any lifetime ) . In some embodiments , neuroinvasive viruses 
type of immune response , including , but not limited to , exhibit periods of dormancy followed by repeat disease . 
innate immune responses ( e.g. , activation of Toll receptor As used herein , the term “ non - neuroinvasive ” refers to a 
signaling cascade ) cell - mediated immune responses ( e.g. , virus or other microorganism that lacks neuroinvasive prop 
responses mediated by T cells ( e.g. , antigen - specific T cells ) 60 erties . 
and non - specific cells of the immune system ) and humoral As used herein , the term “ virulent ” refers to a microor 
immune responses ( e.g. , responses mediated by B cells ( e.g. , ganism ( e.g. , virus ) that is able to cause disease or symptoms 
via generation and secretion of antibodies into the plasma , of disease in a subject . 
lymph , and / or tissue fluids ) . The term “ immune response ” is As used herein , the term “ avirulent ” refers to virus ( e.g. , 
meant to encompass all aspects of the capability of a 65 variant herpesvirus or alphaherpesvirus of embodiments of 
subject's immune system to respond to antigens and / or the present disclosure ) that has reduced or no virulence ( e.g. , 
immunogens ( e.g. , both the initial response to an immuno does not cause disease or symptoms of disease ) . 
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DETAILED DESCRIPTION OF THE response ( e.g. , an adjuvant ) . In some embodiments , the 
DISCLOSURE presence of one or more co - factors or agents reduces the 
amount of antigen required for induction of an immune 
Provided herein are compositions and methods for vac response ( e.g. , a protective immune response ( e.g. , protec 
cination and research applications . In particular , provided 5 tive immunization ) ) . In some embodiments , the presence of 
herein are non - neuroinvasive herpesviruses and alpha her one or more co - factors or agents can be used to skew the 
pesviruses and uses thereof . immune response towards a cellular ( e.g. , T cell mediated ) 
Alpha - herpesviruses enter the nervous system following or humoral ( e.g. , antibody mediated ) immune response . The 
initial replication at exposed body surfaces . This neuroin present disclosure is not limited by the type of co - factor or 
vasive property is a critical step to the establishment of 10 agent used in a therapeutic agent of the present disclosure . 
life - long infection . However , this property is un - desirable Adjuvants are described in general in Vaccine Design 
for clinical applications such as vaccines and cancer therapy . the Subunit and Adjuvant Approach , edited by Powell and 
Accordingly , in some embodiments , the present disclo Newman , Plenum Press , New York , 1995. The present 
sure provides a non - neuroinvasive herepsvirus or alphaher disclosure is not limited by the type of adjuvant utilized 
pesvirus . In some embodiments , the virus comprises one or 15 ( e.g. , for use in a composition ( e.g. , pharmaceutical com 
more mutation in the R2 domain . Examples include , for position ) . For example , in some embodiments , suitable 
example , a variant herpes simplex virus 1 or 2 particle adjuvants include an aluminium salt such as aluminium 
comprising a mutant UL37 protein , wherein said mutant hydroxide gel ( alum ) or aluminium phosphate . In some 
UL37 protein comprises one or more mutations selected embodiments , an adjuvant may be a salt of calcium , iron or 
from Q403A , E452A , Q455A , Q511A , or R515A ; a variant 20 zinc , or may be an insoluble suspension of acylated tyrosine , 
varicella zoster virus particle comprising a mutant UL37 or acylated sugars , cationically or anionically derivatised 
protein , wherein said mutant UL37 protein comprises one or polysaccharides , or polyphosphazenes . 
more mutations selected from Q363A , D413A , Q416A , In general , an immune response is generated to an antigen 
Q472A , or R476A ; and a variant pseudorabies virus particle through the interaction of the antigen with the cells of the 
comprising a mutant UL37 protein , wherein said mutant 25 immune system . Immune responses may be broadly catego 
UL37 protein comprises one or more mutations selected rized into two categories : humoral and cell mediated 
from Q324A , D362A , R365A , H421 A , or H425A . In some immune responses ( e.g. , traditionally characterized by anti 
embodiments , the one or more mutations is two or more body and cellular effector mechanisms of protection , respec 
( e.g. , three , four , or all ) of the mutations . In some embodi tively ) . These categories of response have been termed 
ments , the virus particle exhibits reduced neuro - invasive- 30 Th - type responses ( cell - mediated response ) , and B cell 
ness relative to a virus particle lacking the mutations . In responses ( humoral response ) . 
some embodiments , the virus is avirulent . Stimulation of an immune response can result from a 
The present disclosure is not limited particular herpes direct or indirect response of a cell or component of the 
or alpha herpes viruses . Examples include , but are not immune system to an intervention ( e.g. , exposure to an 
limited to , herpes simplex virus - 1 ( HSV - 1 ) , herpes simplex 35 antigen or immunogen ) . Immune responses can be measured 
virus - 2 ( HSV - 2 ) , pseudorabies virus ( PRV ) , varicella - zoster in many ways including activation , proliferation or differ 
virus ( VRV ) , bovine herpesvirus - 1 ( BHV - 1 ; causative agent entiation of cells of the immune system ( e.g. , B cells ; T cells ; 
of bovine infectious rhinotracheitis and pustular vulvovagi APCs such as for example dendritic cells and macrophages , 
nitis ) , bovine herpes virus 5 ( BHV - 5 ; causative agent of NK cells , NKT cells etc. ) ; up - regulated or down - regulated 
meningoencephalitis and respiratory disease in cattle and 40 expression of markers and cytokines ; stimulation of IgA , 
sheep ) ; equine herpes virus 1 ( EHV - 1 ; causative agent of IgM , or IgG titer ; splenomegaly ( including increased spleen 
equine abortions and respiratory disease ) ; equine herpes cellularity ) ; hyperplasia and mixed cellular infiltrates in 
virus 3 ( EHV - 3 ; causative agent of equine coital exan various organs . Other responses , cells , and components of 
thema ) ; and equine herpes virus 4 ( EHV - 4 ; causative agent of the immune system that can be assessed with respect to 
equine rhinopneumonitis ) . Mutations in the R2 domain of 45 immune stimulation are known in the art . 
the described viruses are identified using the methods In some embodiments , the present disclosure provides a 
described herein ( e.g. , by homology to PRV and as described method of stimulating a Th1 - type immune response in a 
in Examples 2-4 ) . subject comprising administering to a subject a composition 
The non - neuroinvasive viruses described herein find use comprising a non - neuroinvasive herpes or alphaherpes 
in a variety of research , screening , and therapeutic applica- 50 virus . However , in other embodiments , the present disclo 
tions ( e.g. , for use in preparing vaccine and oncolytic virus sure provides a method of stimulating a Th2 - type immune 
compositions ) response in a subject ( e.g. , if balancing of a T cell mediated 
I. Compositions response is desired ) comprising administering to a subject a 
In some embodiments , the present disclosure provides composition comprising a non - neuroinvasive herpes or 
vaccine and / or pharmaceutical compositions comprising a 55 alphaherpes virus . In further preferred embodiments , adju 
variant herpesvirus described herein . The present disclosure vants can be used ( e.g. , can be co - administered with a 
is not limited by the particular formulation of a composition . composition of the present disclosure ) to skew an immune 
Indeed , a vaccine or pharmaceutical composition of the response toward either a Thl or Th2 type immune response . 
present disclosure may comprise one or more different For example , adjuvants that induce Th2 or weak Th1 
agents in addition to the variant herpesvirus . These agents or 60 responses include , but are not limited to , alum , saponins , and 
cofactors include , but are not limited to , adjuvants , surfac SB - As4 . Adjuvants that induce Thl responses include but 
tants , additives , buffers , solubilizers , chelators , oils , salts , are not limited to MPL , MDP , ISCOMS , IL - 12 , IFN - y , and 
therapeutic agents , drugs , bioactive agents , antibacterials , SB - AS2 . 
and antimicrobial agents ( e.g. , antibiotics , antivirals , etc. ) . In Several other types of Th1 - type immunogens can be used 
some embodiments , a vaccine composition comprising a 65 ( e.g. , as an adjuvant ) in compositions and methods of the 
variant herpesvirus comprises an agent and / or co - factor that present disclosure . These include , but are not limited to , the 
enhance the ability of the antigen to induce an immune following . In some embodiments , monophosphoryl lipid A 
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( e.g. , in particular 3 - de - O - acylated monophosphoryl lipid A aluminium hydroxide ( See , e.g. , Brazolot - Millan et al . , Proc . 
( 3D - MPL ) ) , is used . 3D - MPL is a well known adjuvant Natl . Acad Sci . , USA , 1998 , 95 ( 26 ) , 15553-8 ) . 
manufactured by Ribi Immunochem , Montana . Chemically In some embodiments , adjuvants such as Complete Fre 
it is often supplied as a mixture of 3 - de - O - acylated mono unds Adjuvant and Incomplete Freunds Adjuvant , cytokines 
phosphoryl lipid A with either 4 , 5 , or 6 acylated chains . In 5 ( e.g. , interleukins ( e.g. , IL - 2 , IFN - Y , IL - 4 , etc. ) , macrophage 
some embodiments , diphosphoryl lipid A , and 3 - O - deacy colony stimulating factor , tumor necrosis factor , etc. ) , 
lated variants thereof are used . Each of these immunogens detoxified mutants of a bacterial ADP - ribosylating toxin 
can be purified and prepared by methods described in GB such as a cholera toxin ( CT ) , a pertussis toxin ( PT ) , or an E. 
2122204B , hereby incorporated by reference in its entirety . Coli heat - labile toxin ( LT ) , particularly LT - K63 ( where Other purified and synthetic lipopolysaccharides have been 10 lysine is substituted for the wild - type amino acid at position 63 ) LT - R72 ( where arginine is substituted for the wild - type described ( See , e.g. , U.S. Pat . No. 6,005,099 and EP 0 729 amino acid at position 72 ) , CT - S109 ( where serine is sub 473 ; Hilgers et al . , 1986 , Int . Arch . Allergy . Immunol . , stituted for the wild - type amino acid at position 109 ) , and 79 ( 4 ) : 392-6 ; Hilgers et al . , 1987 , Immunology , 60 ( 1 ) : 141-6 ; PT - K9 / G129 ( where lysine is substituted for the wild - type and EP 0 549 074 , each of which is hereby incorporated by 15 amino acid at position 9 and glycine substituted at position 
reference in its entirety ) . In some embodiments , 3D - MPL is 129 ) ( See , e.g. , WO93 / 13202 and W092 / 19265 , each of 
used in the form of a particulate formulation ( e.g. , having a which is hereby incorporated by reference ) , and other immu 
small particle size less than 0.2 um in diameter , described in nogenic substances ( e.g. , that enhance the effectiveness of a 
EP 0 689 454 , hereby incorporated by reference in its composition of the present disclosure ) are used with a 
entirety ) . 20 composition comprising a non - neuroinvasive herpes or 
In some embodiments , saponins are used as an adjuvant alphaherpes virus of the present disclosure . 
( e.g. , Th1 - type adjuvant ) in a composition of the present Additional examples of adjuvants that find use in the 
disclosure . Saponins are well known adjuvants ( See , e.g. , present disclosure include poly ( di ( carboxylatophenoxy ) 
Lacaille - Dubois and Wagner ( 1996 ) Phytomedicine vol 2 pp phosphazene ( PCPP polymer ; Virus Research Institute , 
363-386 ) . Examples of saponins include Quil A ( derived 25 USA ) ; derivatives of lipopolysaccharides such as mono 
from the bark of the South American tree Quillaja Saponaria phosphoryl lipid A ( MPL ; Ribi ImmunoChem Research , 
Molina ) , and fractions thereof ( See , e.g. , U.S. Pat . No. Inc. , Hamilton , Mont . ) , muramyl dipeptide ( MDP ; Ribi ) and 
5,057,540 ; Kensil , Crit Rev Ther Drug Carrier Syst , 1996 , threonyl - muramyl dipeptide ( t - MDP : Ribi ) ; OM - 174 ( a glu 
12 ( 1-2 ) : 1-55 ; and EP 0 362 279 , each of which is hereby cosamine disaccharide related to lipid A ; OM Pharma SA , 
incorporated by reference in its entirety ) . Also contemplated 30 Meyrin , Switzerland ) ; and Leishmania elongation factor ( a 
to be useful in the present disclosure are the haemolytic purified Leishmania protein ; Corixa Corporation , Seattle , 
saponins QS7 , QS17 , and QS21 ( HPLC purified fractions of Wash . ) . 
Quil A ; See , e.g. , Kensil et al . ( 1991 ) . J. Immunology Adjuvants may be added to a composition comprising a 
146,431-437 , U.S. Pat . No. 5,057,540 ; WO 96/33739 ; WO non - neuroinvasive herpes or alphaherpes virus , or , the adju 
96/11711 and EP 0 362 279 , each of which is hereby 35 vant may be formulated with carriers , for example lipo 
incorporated by reference in its entirety ) . Also contemplated somes , or metallic salts ( e.g. , aluminium salts ( e.g. , alu 
to be useful are combinations of QS21 and polysorbate or minium hydroxide ) ) prior to combining with 
cyclodextrin ( See , e.g. , WO 99/10008 , hereby incorporated co - administration with a composition . 
by reference in its entirety . In some embodiments , a composition comprising a non 
In some embodiments , an immunogenic oligonucleotide 40 neuroinvasive herpes or alphaherpes virus comprises a 
containing unmethylated CpG dinucleotides ( “ CpG ” ) is single adjuvant . In other embodiments , a composition com 
used as an adjuvant . CpG is an abbreviation for cytosine prises two or more adjuvants ( See , e.g. , WO 94/00153 ; WO 
guanosine dinucleotide motifs present in DNA . CpG is 95/17210 ; WO 96/33739 ; WO 98/56414 ; WO 99/12565 ; 
known in the art as being an adjuvant when administered by WO 99/11241 ; and WO 94/00153 , each of which is hereby 
both systemic and mucosal routes ( See , e.g. , WO 96/02555 , 45 incorporated by reference in its entirety ) . 
EP 468520 , Davis et al . , J. Immunol , 1998 , 160 ( 2 ) : 870-876 ; In some embodiments , a composition comprising an 
McCluskie and Davis , J. Immunol . , 1998 , 161 ( 9 ) : 4463-6 ; antigen or immunogen comprises one or more mucoadhe 
and U.S. Pat . App . No. 20050238660 , each of which is sives ( See , e.g. , U.S. Pat . App . No. 20050281843 , hereby 
hereby incorporated by reference in its entirety ) . For incorporated by reference in its entirety ) . The present dis 
example , in some embodiments , the immunostimulatory 50 closure is not limited by the type of mucoadhesive utilized . 
sequence is Purine - Purine - C - G - pyrimidine - pyrimidine ; Indeed , a variety of mucoadhesives are contemplated to be 
wherein the CG motif is not methylated . useful in the present disclosure including , but not limited to , 
Although an understanding of the mechanism is not cross - linked derivatives of poly ( acrylic acid ) ( e.g. , carbopol 
necessary to practice the present disclosure and the present and polycarbophil ) , polyvinyl alcohol , polyvinyl pyroll 
disclosure is not limited to any particular mechanism of 55 done , polysaccharides ( e.g. , alginate and chitosan ) , hydroxy 
action , in some embodiments , the presence of one or more propyl methylcellulose , lectins , fimbrial proteins , and car 
CpG oligonucleotides activate various immune subsets boxymethylcellulose . Although an understanding of the 
including natural killer cells ( which produce IFN - y ) and mechanism is not necessary to practice the present disclo 
macrophages . In some embodiments , CpG oligonucleotides sure and the present disclosure is not limited to any particu 
are formulated into a composition of the present disclosure 60 lar mechanism of action , in some embodiments , use of a 
for inducing an immune response . In some embodiments , a mucoadhesive ( e.g. , in a composition comprising a non 
free solution of CpG is co - administered together with an neuroinvasive herpes or alphaherpes virus ) enhances induc 
antigen ( e.g. , present within a solution ( See , e.g. , WO tion of an immune response in a subject ( e.g. , administered 
96/02555 ; hereby incorporated by reference ) . In some a composition of the present disclosure ) due to an increase 
embodiments , a CpG oligonucleotide is covalently conju- 65 in duration and / or amount of exposure to a non - neuroinva 
gated to an antigen ( See , e.g. , WO 98/16247 , hereby incor sive herpes or alphaherpes virus that a subject experiences 
porated by reference ) , or formulated with a carrier such as when a mucoadhesive is used compared to the duration 
or 
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and / or amount of exposure to a non - neuroinvasive herpes or routes include intravaginal and intra - rectal routes . In pre 
alphaherpes virus in the absence of using the mucoadhesive . ferred embodiments of the present disclosure , a nasal route 
In some embodiments , a composition of the present of administration is used , termed “ intranasal administration ” 
disclosure may comprise sterile aqueous preparations . or “ intranasal vaccination ” herein . Methods of intranasal 
Acceptable vehicles and solvents include , but are not limited 5 vaccination are well known in the art , including the admin 
to , water , istration of a droplet or spray form of the vaccine into the 
Ringer's solution , phosphate buffered saline and isotonic nasopharynx of a subject to be immunized . In some embodi 
sodium chloride solution . In addition , sterile , fixed oils are ments , a nebulized or aerosolized composition is provided . 
conventionally employed as a solvent or suspending Enteric formulations such as gastro resistant capsules for 
medium . For this purpose any bland fixed mineral or non- 10 oral administration , suppositories for rectal or vaginal 
mineral oil may be employed including synthetic mono administration also form part of this disclosure . Composi 
ordi - glycerides . In addition , fatty acids such as oleic acid tions of the present disclosure may also be administered via 
find use in the preparation of injectables . Carrier formula the oral route . Under these circumstances , a composition 
tions suitable for mucosal , subcutaneous , intramuscular , comprising a non - neuroinvasive herpes or alphaherpes virus 
intraperitoneal , intravenous , or administration via other 15 may comprise a pharmaceutically acceptable excipient and / 
routes may be found in Remington's Pharmaceutical Sci or include alkaline buffers , or enteric capsules . Formulations 
ences , Mack Publishing Company , Easton , Pa . for nasal delivery may include those with dextran or cyclo 
A composition comprising a variant viral particle of the dextran and saponin as an adjuvant . 
present disclosure can be used therapeutically ( e.g. , to Compositions of the present disclosure may also be 
enhance an immune response ) or as a prophylactic ( e.g. , for 20 administered via a vaginal route . In such cases , a composi 
immunization ( e.g. , to prevent signs or symptoms of dis tion comprising a non - neuroinvasive herpes or alphaherpes 
ease ) ) or as an oncolytic virus . A composition can be virus may comprise pharmaceutically acceptable excipients 
administered to a subject via a number of different delivery and / or emulsifiers , polymers ( e.g. , CARBOPOL ) , and other 
routes and methods . known stabilizers of vaginal creams and suppositories . In 
In some embodiments , compositions of the present dis- 25 some embodiments , compositions of the present disclosure 
closure are administered mucosally ( e.g. , using standard are administered via a rectal route . In such cases , composi 
techniques ; See , e.g. , Remington : The Science and Practice tions may comprise excipients and / or waxes and polymers 
of Pharmacy , Mack Publishing Company , Easton , Pa . , 19th known in the art for forming rectal suppositories . 
edition , 1995 ( e.g. , for mucosal delivery techniques , includ In some embodiments , the same route of administration 
ing intranasal , pulmonary , vaginal and rectal techniques ) , as 30 ( e.g. , mucosal administration ) is chosen for both a priming 
well as European Publication No. 517,565 and Illum et al . , and boosting vaccination . In some embodiments , multiple 
J. Controlled Rel . , 1994 , 29 : 133-141 ( e.g. , for techniques of routes of administration are utilized ( e.g. , at the same time , 
intranasal administration ) , including via cell , vesicles , and or , alternatively , sequentially ) in order to stimulate an 
liposomes , each of which is hereby incorporated by refer immune response . 
ence in its entirety ) . Alternatively , the compositions of the 35 For example , in some embodiments , a composition com 
present disclosure may be administered dermally or trans prising a non - neuroinvasive herpes or alphaherpes virus is 
dermally , using standard techniques ( See , e.g. , Remington : administered to a mucosal surface of a subject in either a 
The Science arid Practice of Pharmacy , Mack Publishing priming or boosting vaccination regime . Alternatively , in 
Company , Easton , Pa . , 19th edition , 1995 ) . The present some embodiments , the composition is administered sys 
disclosure is not limited by the route of administration . 40 temically in either a priming or boosting vaccination regime . 
Although an understanding of the mechanism is not In some embodiments , a composition is administered to a 
necessary to practice the present disclosure and the present subject in a priming vaccination regimen via mucosal 
disclosure is not limited to any particular mechanism of administration and a boosting regimen via systemic admin 
action , in some embodiments , mucosal vaccination is the istration . In some embodiments , a composition is adminis 
preferred route of administration as it has been shown that 45 tered to a subject in a priming vaccination regimen via 
mucosal administration of antigens has a greater efficacy of systemic administration and a boosting regimen via mucosal 
inducing protective immune responses at mucosal surfaces administration . Examples of systemic routes of administra 
( e.g. , mucosal immunity ) , the route of entry of many patho tion include , but are not limited to , a parenteral , intramus 
gens . In addition , mucosal vaccination , such as intranasal cular , intradermal , transdermal , subcutaneous , intraperito 
vaccination , may induce mucosal immunity not only in the 50 neal intravenous administration . A composition 
nasal mucosa , but also in distant mucosal sites such as the comprising a non - neuroinvasive herpes or alphaherpes virus 
genital mucosa ( See , e.g. , Mestecky , Journal of Clinical may be used for both prophylactic and therapeutic purposes . 
Immunology , 7 : 265-276 , 1987 ) . More advantageously , in In some embodiments , compositions of the present dis 
further preferred embodiments , in addition to inducing closure are administered by pulmonary delivery . For 
mucosal immune responses , mucosal vaccination also 55 example , a composition of the present disclosure can be 
induces systemic immunity . In some embodiments , non delivered to the lungs of a subject ( e.g. , a human ) via 
parenteral administration ( e.g. , muscosal administration of inhalation ( e.g. , thereby traversing across the lung epithelial 
vaccines ) provides an efficient and convenient way to boost lining to the blood stream ( See , e.g. , Adjei , et al . Pharma 
systemic immunity ( e.g. , induced by parenteral or mucosal ceutical Research 1990 ; 7 : 565-569 ; Adjei , et al . Int . J. 
vaccination ( e.g. , in cases where multiple boosts are used to 60 Pharmaceutics 1990 ; 63 : 135-144 ; Braquet , et al . J. Cardio 
sustain a vigorous systemic immunity ) ) . vascular Pharmacology 1989 143-146 ; Hubbard , et al . 
In some embodiments , a composition comprising a non ( 1989 ) Annals of Internal Medicine , Vol . III , pp . 206-212 ; 
neuroinvasive herpes or alphaherpes virus of the present Smith , et al . J. Clin . Invest . 1989 ; 84 : 1145-1146 ; Oswein , et 
disclosure may be used to protect or treat a subject suscep al . “ Aerosolization of Proteins ” , 1990 ; Proceedings of Sym 
tible to , or suffering from , disease by means of administering 65 posium on Respiratory Drug Delivery II Keystone , Colo 
a composition of the present disclosure via a mucosal route rado ; Debs , et al . J. Immunol . 1988 ; 140 : 3482-3488 ; and 
( e.g. , an oral / alimentary or nasal route ) . Alternative mucosal U.S. Pat . No. 5,284,656 to Platz , et al , each of which are 
or 
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hereby incorporated by reference in its entirety ) . A method a population of a region , city , state and / or country ) for their 
and composition for pulmonary delivery of drugs for sys own health ( e.g. , to prevent or treat disease ) . In some 
temic effect is described in U.S. Pat . No.5,451,569 to Wong , embodiments , the subjects are non - human mammals ( e.g. , 
et al . , hereby incorporated by reference ; See also U.S. Pat . pigs , cattle , goats , horses , sheep , or other livestock ; or mice , 
No. 6,651,655 to Licalsi et al . , hereby incorporated by 5 rats , rabbits or other animal ) . In some embodiments , com 
reference in its entirety ) ) . positions and methods of the present disclosure are utilized 
Further contemplated for use in the practice of this in research settings ( e.g. , with research animals ) . 
disclosure are a wide range of mechanical devices designed A composition of the present disclosure may be formu 
for pulmonary and / or nasal mucosal delivery of pharmaceu lated for administration by any route , such as mucosal , oral , 
tical agents including , but not limited to , nebulizers , metered 10 transdermal , intranasal , intramuscular , parenteral or other 
dose inhalers , and powder inhalers , all of which are familiar route described herein . The compositions may be in any one 
to those skilled in the art . Some specific examples of or more different forms including , but not limited to , tablets , 
commercially available devices suitable for the practice of capsules , powders , granules , lozenges , foams , creams or 
this disclosure are the Ultravent nebulizer ( Mallinckrodt liquid preparations . 
Inc. , St. Louis , Mo. ) ; the Acorn II nebulizer ( Marquest 15 Topical formulations of the present disclosure may be 
Medical Products , Englewood , Colo . ) ; the Ventolin metered presented as , for instance , ointments , creams or lotions , 
dose inhaler ( Glaxo Inc. , Research Triangle Park , N.C. ) ; and foams , and aerosols , and may contain appropriate conven 
the Spinhaler powder inhaler ( Fisons Corp. , Bedford , tional additives such as preservatives , solvents ( e.g. , to assist 
Mass . ) . All such devices require the use of formulations penetration ) , and emollients in ointments and creams . 
suitable for dispensing of the therapeutic agent . Typically , 20 Topical formulations may also include agents that 
each formulation is specific to the type of device employed enhance penetration of the active ingredients through the 
and may involve the use of an appropriate propellant mate skin . Exemplary agents include a binary combination of 
rial , in addition to the usual diluents , adjuvants , surfactants , N- (hydroxyethyl ) pyrrolidone and a cell - envelope disorder 
carriers and / or other agents useful in therapy . Also , the use ing compound , a sugar ester in combination with a sulfoxide 
of liposomes , microcapsules or microspheres , inclusion 25 or phosphine oxide , and sucrose monooleate , decyl methyl 
complexes , or other types of carriers is contemplated . sulfoxide , and alcohol . 
Thus , in some embodiments , a composition comprising Other exemplary materials that increase skin penetration 
an variant virus of the present disclosure may be used to include surfactants or wetting agents including , but not 
protect and / or treat a subject susceptible to , or suffering limited to , polyoxyethylene sorbitan mono - oleoate ( Poly 
from , a disease by means of administering the composition 30 sorbate 80 ) ; sorbitan mono - oleate ( Span 80 ) ; p - isooctyl 
by mucosal , intramuscular , intraperitoneal , intradermal , polyoxyethylene - phenol polymer ( Triton WR - 1330 ) ; poly 
transdermal , pulmonary , intravenous , subcutaneous or other oxyethylene sorbitan tri - oleate ( Tween 85 ) ; dioctyl sodium 
route of administration described herein . Methods of sys sulfosuccinate ; and sodium sarcosinate ( Sarcosyl NL - 97 ) ; 
temic administration of the vaccine preparations may and other pharmaceutically acceptable surfactants . 
include conventional syringes and needles , or devices 35 In certain embodiments of the disclosure , compositions 
designed for ballistic delivery of solid vaccines ( See , e.g. , may further comprise one or more alcohols , zinc - containing 
WO 99/27961 , hereby incorporated by reference ) , or needle compounds , emollients , humectants , thickening and / or gell 
less pressure liquid jet device ( See , e.g. , U.S. Pat . Nos . ing agents , neutralizing agents , and surfactants . Water used 
4,596,556 ; 5,993,412 , each of which are hereby incorpo in the formulations is preferably deionized water having a 
rated by reference ) , or transdermal patches ( See , e.g. , WO 40 neutral pH . Additional additives in the topical formulations 
97/48440 ; WO 98/28037 , each of which are hereby incor include , but are not limited to , silicone fluids , dyes , fra 
porated by reference ) . The present disclosure may also be grances , pH adjusters , and vitamins . Topical formulations 
used to enhance the immunogenicity of antigens applied to may also contain compatible conventional carriers , such as 
the skin ( transdermal or transcutaneous delivery , See , e.g. , cream or ointment bases and ethanol or oleyl alcohol for 
WO 98/20734 ; WO 98/28037 , each of which are hereby 45 lotions . Such carriers may be present as from about 1 % up 
incorporated by reference ) . to about 98 % of the formulation . The ointment base can 
The present disclosure is not limited by the type of subject comprise one or more of petrolatum , mineral oil , ceresin , 
administered ( e.g. , in order to stimulate an immune response lanolin alcohol , panthenol , glycerin , bisabolol , cocoa butter 
( e.g. , in order to generate protective immunity ( e.g. , mucosal and the like . 
and / or systemic immunity ) or to target cancer cells ) a 50 In some embodiments , pharmaceutical compositions of 
composition of the present disclosure . Indeed , a wide variety the present disclosure may be formulated and used as foams . 
of subjects are contemplated to be benefited from adminis Pharmaceutical foams include formulations such as , but not 
tration of a composition of the present disclosure . In some limited to , emulsions , microemulsions , creams , jellies and 
embodiments , the subject is a human or non - human animal . liposomes . While basically similar in nature these formula 
In some embodiments , human subjects are of any age ( e.g. , 55 tions vary in the components and the consistency of the final 
adults , children , infants , etc. ) that have been or are likely to product . The compositions of the present disclosure may 
become exposed to a microorganism ( e.g. , herpesvirus ) . In additionally contain other adjunct components convention 
some embodiments , the human subjects are subjects that are ally found in pharmaceutical compositions . Thus , for 
more likely to receive a direct exposure to pathogenic example , the compositions may contain additional , compat 
microorganisms or that are more likely to display signs and 60 ible , pharmaceutically - active materials such as , for example , 
symptoms of disease after exposure to a pathogen ( e.g. , antipruritics , astringents , local anesthetics or anti - inflamma 
immune suppressed subjects ) . In some embodiments , the tory agents , or may contain additional materials useful in 
general public is administered ( e.g. , vaccinated with ) a physically formulating various dosage forms of the compo 
composition of the present disclosure ( e.g. , to prevent the sitions of the present disclosure , such as dyes , flavoring 
occurrence or spread of disease ) . For example , in some 65 agents , preservatives , antioxidants , opacifiers , thickening 
embodiments , compositions and methods of the present agents and stabilizers . However , such materials , when 
disclosure are utilized to vaccinate a group of people ( e.g. , added , preferably do not unduly interfere with the biological 
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activities of the components of the compositions of the inhibit dihydrofolate reduction , inhibit DNA synthesis , form 
present disclosure . The formulations can be sterilized and , if adducts with DNA , damage DNA , inhibit DNA repair , 
desired , mixed with auxiliary agents ( e.g. , lubricants , pre intercalate with DNA , deaminate asparagines , inhibit RNA 
servatives , stabilizers , wetting agents , emulsifiers , salts for synthesis , inhibit protein synthesis or stability , inhibit micro 
influencing osmotic pressure , buffers , colorings , flavorings 5 tubule synthesis or function , and the like . 
and / or aromatic substances and the like ) that do not delete In some embodiments , exemplary anticancer agents suit 
riously interact with the non - neuroinvasive herpes or alpha able for use in compositions and methods of the present 
herpes virus or other components of the formulation . In disclosure include , but are not limited to : 1 ) alkaloids , 
some embodiments , immunostimulatory compositions of including microtubule inhibitors ( e.g. , vincristine , vinblas 
the present disclosure are administered in the form of a 10 tine , and vindesine , etc. ) , microtubule stabilizers ( e.g. , pacli 
pharmaceutically acceptable salt . When used the salts taxel ( TAXOL ) , and docetaxel , etc. ) , and chromatin function 
should be pharmaceutically acceptable , but non - pharmaceu inhibitors , including topoisomerase inhibitors , such as epi 
tically acceptable salts may conveniently be used to prepare podophyllotoxins ( e.g. , etoposide ( VP - 16 ) , and teniposide 
pharmaceutically acceptable salts thereof . Such salts ( VM - 26 ) , etc. ) , and agents that target topoisomerase I ( e.g. , 
include , but are not limited to , those prepared from the 15 camptothecin and isirinotecan ( CPT - 11 ) , etc. ) ; 2 ) covalent following acids : hydrochloric , hydrobromic , sulphuric , DNA - binding agents ( alkylating agents ) , including nitrogen 
nitric , phosphoric , maleic , acetic , salicylic , p - toluene sul mustards ( e.g. , mechlorethamine , chlorambucil , cyclophos 
phonic , tartaric , citric , methane sulphonic , formic , malonic , phamide , ifosphamide , and busulfan ( MYLERAN ) , etc. ) , 
succinic , naphthalene - 2 - sulphonic , and benzene sulphonic . nitrosoureas ( e.g. , carmustine , lomustine , and semustine , 
Also , such salts can be prepared as alkaline metal or alkaline 20 etc. ) , and other alkylating agents ( e.g. , dacarbazine , 
earth salts , such as sodium , potassium or calcium salts of the hydroxymethylmelamine , thiotepa , and mitomycin , etc. ) ; 3 ) 
carboxylic acid group . noncovalent DNA - binding agents ( antitumor antibiotics ) , 
Suitable buffering agents include , but are not limited to , including nucleic acid inhibitors ( e.g. , dactinomycin ( actino 
acetic acid and a salt ( 1-2 % w / v ) ; citric acid and a salt ( 1-3 % mycin D ) , etc. ) , anthracyclines ( e.g. , daunorubicin ( dauno 
w / v ) ; boric acid and a salt ( 0.5-2.5 % w / v ) ; and phosphoric 25 mycin , and cerubidine ) , doxorubicin ( adriamycin ) , and ida 
acid and a salt ( 0.8-2 % w / v ) . Suitable preservatives may rubicin ( idamycin ) , etc. ) , anthracenediones ( e.g. , 
include benzalkonium chloride ( 0.003-0.03 % w / v ) ; chlo anthracycline analogues , such as mitoxantrone , etc. ) , bleo 
robutanol ( 0.3-0.9 % w / v ) ; parabens ( 0.01-0.25 % w / v ) and mycins ( BLENOXANE ) , etc. , and plicamycin ( mithramy 
thimerosal ( 0.004-0.02 % w / v ) . cin ) , etc .; 4 ) antimetabolites , including antifolates ( e.g. , 
In some embodiments , vaccine compositions are co- 30 methotrexate , FOLEX , and MEXATE , etc. ) , purine antime 
administered with one or more antibiotics or antiviral tabolites ( e.g. , 6 - mercaptopurine ( 6 - MP , PURINETHOL ) , 
agents . There are an enormous amount of antimicrobial 6 - thioguanine ( 6 - TG ) , azathioprine , acyclovir , ganciclovir , 
agents currently available for use in treating bacterial , fungal chlorodeoxyadenosine , 2 - chlorodeoxyadenosine ( CDA ) , and 
and viral infections . For a comprehensive treatise on the 2 ' - deoxycoformycin ( pentostatin ) , etc. ) , pyrimidine antago 
general classes of such drugs and their mechanisms of 35 nists ( e.g. , fluoropyrimidines ( e.g. , 5 - fluorouracil ( ADRU 
action , the skilled artisan is referred to Goodman & Gil CIL ) , 5 - fluorodeoxyuridine ( FdUrd ) ( floxuridine ) ) etc. ) , and 
man's “ The Pharmacological Basis of Therapeutics ” Eds . cytosine arabinosides ( e.g. , CYTOSAR ( ara - C ) and fludara 
Hardman et al . , 9th Edition , Pub . McGraw Hill , chapters 43 bine , etc. ) ; 5 ) enzymes , including L - asparaginase , and 
through 50 , 1996 , ( herein incorporated by reference in its hydroxyurea , etc .; 6 ) hormones , including glucocorticoids , 
entirety ) . Generally , these agents include agents that inhibit 40 antiestrogens ( e.g. , tamoxifen , etc. ) , nonsteroidal antiandro 
cell wall synthesis ( e.g. , penicillins , cephalosporins , cyclos gens ( e.g. , flutamide , etc. ) , and aromatase inhibitors ( e.g. , 
erine , vancomycin , bacitracin ) ; and the imidazole antifungal anastrozole ( ARIMIDEX ) , etc. ) ; 7 ) platinum compounds 
agents ( e.g. , miconazole , ketoconazole and clotrimazole ) ; ( e.g. , cisplatin and carboplatin , etc. ) ; 8 ) monoclonal anti 
agents that act directly to disrupt the cell membrane of the bodies conjugated with anticancer drugs , toxins , and / or 
microorganism ( e.g. , detergents such as polmyxin and colis- 45 radionuclides , etc .; 9 ) biological response modifiers ( e.g. , 
timethate and the antifungals nystatin and amphotericin B ) ; interferons ( e.g. , IFN - a , etc. ) and interleukins ( e.g. , IL - 2 , 
agents that affect the ribosomal subunits to inhibit protein etc. ) , etc. ) ; 10 ) adoptive immunotherapy ; 11 ) hematopoietic 
synthesis ( e.g. , chloramphenicol , the tetracyclines , erthro growth factors ; 12 ) agents that induce tumor cell differen 
mycin and clindamycin ) ; agents that alter protein synthesis tiation ( e.g. , all - trans - retinoic acid , etc. ) ; 13 ) gene therapy 
and lead to cell death ( e.g. , aminoglycosides ) ; agents that 50 techniques ; 14 ) antisense therapy techniques ; 15 ) tumor 
affect nucleic acid metabolism ( e.g. , the rifamycins and the vaccines ; 16 ) therapies directed against tumor metastases 
quinolones ) ; the antimetabolites ( e.g. , trimethoprim and ( e.g. , batimastat , etc. ) ; 17 ) angiogenesis inhibitors ; 18 ) pro 
sulfonamides ) ; and the nucleic acid analogues such as teosome inhibitors ( e.g. , VELCADE ) ; 19 ) inhibitors of 
zidovudine , gangcyclovir , vidarabine , and acyclovir which acetylation and / or methylation ( e.g. , HDAC inhibitors ) ; 20 ) 
act to inhibit viral enzymes essential for DNA synthesis . 55 modulators of NF kappa B ; 21 ) inhibitors of cell cycle 
Various combinations of antimicrobials may be employed . regulation ( e.g. , CDK inhibitors ) ; 22 ) modulators of p53 
In some embodiments , compositions comprising variant protein function ; and 23 ) radiation . 
viruses are administered in combination with anti - cancer Any oncolytic agent used in a cancer therapy context finds 
( e.g. , chemotherapy agents ) . Various classes of antineoplas use in the compositions and methods of the present inven 
tic ( e.g. , anticancer ) agents are contemplated for use in 60 tion . For example , the U.S. Food and Drug Administration 
certain embodiments of the present disclosure . Anticancer maintains a formulary of oncolytic agents approved for use 
agents suitable for use with the present disclosure include , in the United States . International counterpart agencies to 
but are not limited to , agents that induce apoptosis , agents the U.S.F.D.A. maintain similar formularies . 
that inhibit adenosine deaminase function , inhibit pyrimi In co - administration procedures , the agents may be 
dine biosynthesis , inhibit purine ring biosynthesis , inhibit 65 administered concurrently or sequentially . In one embodi 
nucleotide interconversions , inhibit ribonucleotide reduc ment , the compositions described herein are administered 
tase , inhibit thymidine monophosphate ( TMP ) synthesis , prior to the other active agent ( s ) . The pharmaceutical for 
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mulations and modes of administration may be any of those receives any one or more of the specific dosages provided 
described herein . In addition , the two or more co - adminis herein . In some embodiments , dilution of a concentrated 
tered agents may each be administered using different modes composition may be made such that a subject is adminis 
( e.g. , routes ) or different formulations . The additional agents tered ( e.g. , in a single dose ) . Concentrated compositions are 
to be co - administered ( e.g. , antibiotics , chemotherapy 5 contemplated to be useful in a setting in which large 
agents , adjuvants , etc. ) can be any of the well - known agents numbers of subjects may be administered a composition of 
in the art , including , but not limited to , those that are the present disclosure ( e.g. , an immunization clinic , hospital , 
currently in clinical use . school , etc. ) . In some embodiments , a composition compris 
In some embodiments , a composition comprising a non ing a non - neuroinvasive herpes or alphaherpes virus of the 
neuroinvasive herpes or alphaherpes virus is administered to 10 present disclosure ( e.g. , a concentrated composition ) is 
a subject via more than one route . For example , a subject stable at room temperature for more than 1 week , in some 
that would benefit from having a protective immune embodiments for more than 2 weeks , in some embodiments 
response ( e.g. , immunity ) towards a pathogenic microorgan for more than 3 weeks , in some embodiments for more than 
ism may benefit from receiving mucosal administration 4 weeks , in some embodiments for more than 5 weeks , and 
( e.g. , nasal administration or other mucosal routes described 15 in some embodiments for more than 6 weeks . 
herein ) and , additionally , receiving one or more other routes The present disclosure further provides kits comprising 
of administration ( e.g. , parenteral or pulmonary administra the vaccine or pharmaceutical compositions comprised 
tion ( e.g. , via a nebulizer , inhaler , or other methods herein . In some embodiments , the kit includes all of the 
described herein ) . In some embodiments , administration via components necessary , sufficient or useful for administering 
mucosal route is sufficient to induce both mucosal as well as 20 the vaccine . For example , in some embodiments , the kits 
systemic immunity towards the herpes or alphaherpes virus . comprise devices for administering the vaccine ( e.g. , 
In other embodiments , administration via multiple routes needles or other injection devices ) , temperature control 
serves to provide both mucosal and systemic immunity . components ( e.g. , refrigeration or other cooling compo 
Thus , although an understanding of the mechanism is not nents ) , sanitation components ( e.g. , alcohol swabs for sani 
necessary to practice the present disclosure and the present 25 tizing the site of injection ) and instructions for administering 
disclosure is not limited to any particular mechanism of the vaccine . 
action , in some embodiments , it is contemplated that a II . Uses 
subject administered a composition of the present disclosure The non - neuroinvasive viruses described herein find use 
via multiple routes of administration ( e.g. , immunization in a variety of research , screening , and therapeutic applica 
( e.g. , mucosal as well as airway or parenteral administration 30 tions . 
of the composition ) may have a stronger immune response Embodiments of the present disclosure provide vaccine 
to a non - neuroinvasive herpes or alphaherpes virus than a compositions for use in the prevention of disease in human 
subject administered a composition via just one route . and non - human animals ( e.g. , livestock and companion 
Other delivery systems can include time - release , delayed animals ) . 
release or sustained release delivery systems . Such systems 35 In some embodiments , the non - neuroinvasive viruses 
can avoid repeated administrations of the compositions , described herein find use in cancer therapy ( e.g. , as oncolytic 
increasing convenience to the subject and a physician . Many viruses ) . An oncolytic virus is a virus that preferentially 
types of release delivery systems are available and known to infects and kills cancer cells . As the infected cancer cells are 
those of ordinary skill in the art . They include polymer based destroyed by lysis , they release new infectious virus par 
systems such as polylactide - glycolide ) , copolyoxalates , 40 ticles to help destroy the remaining tumor . Oncolytic viruses 
polycaprolactones , polyesteramides , polyorthoesters , poly are thought not only to cause direct destruction of the tumor 
hydroxybutyric acid , and polyanhydrides . Microcapsules of cells , but also to stimulate host anti - tumor immune 
the foregoing polymers containing drugs are described in , responses . Oncolytic herpesviruses are described , for 
for example , U.S. Pat . No. 5,075,109 , hereby incorporated example , in Varghese , et al . ( Cancer Gene Therapy 9 ( 12 ) : 
by reference . Delivery systems also include non - polymer 45 967-78 ) . In some embodiments , the modified non - neuroin 
systems that are : lipids including sterols such as cholesterol , vasive viruses described herein find use as oncolytic viruses 
cholesterol esters and fatty acids or neutral fats such as ( e.g. , as described herein or with further modification ) . 
mono - di - and tri - glycerides ; hydrogel release systems ; sylas In some embodiments , the viral compositions described 
tic systems ; peptide based systems ; wax coatings ; com herein find use in vaccination ( e.g. , against herpesvirus and 
pressed tablets using conventional binders and excipients ; 50 alphaherpes virus infection ) . 
partially fused implants ; and the like . Specific examples In some embodiments , following an initial administration 
include , but are not limited to : ( a ) erosional systems in of a composition of the present disclosure ( e.g. , an initial 
which an agent of the disclosure is contained in a form vaccination ) , a subject may receive one or more boost 
within a matrix such as those described in U.S. Pat . Nos . administrations ( e.g. , around 2 weeks , around 3 weeks , 
4,452,775 , 4,675,189 , and 5,736,152 , each of which is 55 around 4 weeks , around 5 weeks , around 6 weeks , around 7 
hereby incorporated by reference and ( b ) diffusional systems weeks , around 8 weeks , around 10 weeks , around 3 months , 
in which an active component permeates at a controlled rate around 4 months , around 6 months , around 9 months , around 
from a polymer such as described in U.S. Pat . Nos . 3,854 , 1 year , around 2 years , around 3 years , around 5 years , 
480 , 5,133,974 and 5,407,686 , each of which is hereby around 10 years ) subsequent to a first , second , third , fourth , 
incorporated by reference . In addition , pump - based hard- 60 fifth , sixth , seventh , eights , ninth , tenth , and / or more than 
ware delivery systems can be used , some of which are tenth administration . Although an understanding of the 
adapted for implantation . mechanism is not necessary to practice the present disclo 
In some embodiments , a vaccine or pharmaceutical com sure and the present disclosure is not limited to any particu 
position of the present disclosure is formulated in a concen lar mechanism of action , in some embodiments , reintroduc 
trated dose that can be diluted prior to administration to a 65 tion of a non - neuroinvasive herpes or alphaherpes virus in a 
subject . For example , dilutions of a concentrated composi boost dose enables vigorous systemic immunity in a subject . 
tion may be administered to a subject such that the subject The boost can be with the same formulation given for the 
5 
US 10,647,964 B2 
19 20 
primary immune response , or can be with a different for tained in Dulbecco modified Eagle medium ( DMEM ; Invit 
mulation that contains the virus . The dosage regimen will rogen ) supplemented with 10 % bovine growth supplement 
also , at least in part , be determined by the need of the subject ( BGS ; HyClone ) , which was reduced to 2 % during trans 
and be dependent on the judgment of a practitioner . fection and infection . The harvested virus was passaged 
Dosage units may be proportionately increased or once to produce a high - titer stock by infecting a 10 - cm dish 
decreased based on several factors including , but not limited of PK15 cells with 1 ul virus . Transfection of pGS4284 
to , the weight , age , and health status of the subject . In resulted in PRV - GS4284 , which upon passage propagated to 
addition , dosage units may be increased or decreased for titers of > 5x108 PFU / ml . To make PRV encoding the pen 
subsequent administrations ( e.g. , boost administrations ) . tuple mutations D79A / D81A / E82A / D382A / D383A in the 
In some embodiments , the compositions described herein 10 calcium - binding region ( Ca ) of UL37 , codon changes were 
find use in research uses ( e.g. , to identify neurons in cells introduced through two rounds of en passant mutagenesis of 
and non - human animals ) . For example , in some embodi PGS4284 . The first set of primers , 5 = CTCGCCGAGAAC 
ments , the modified viruses described herein find use as CTGGC CGGCCTGGCGCTGTGGCGCCTGCGC 
anterograde - specific trans - synaptic tracers of the mamma CACGCCTGGGCCGCGGGCACGGCCCCGCT GAG 
lian nervous system . 15 GATGACGACGATAAGTAGGG ( SEQ ID NO : 5 ) and 
5 = GTCGCCGTTGACGACCCCCAGGAGCTCCAGCA 
EXPERIMENTAL GCGGGGCCGTGCCCGCGGCC CAGGCGTGGCGCA 
GGCGCCACAACCAATTAACCAATTCTGATTAG ( SEQ 
The following examples are provided in order to demon ID NO : 6 ) , was used to generate the D382A / D383A muta 
strate and further illustrate certain preferred embodiments 20 tions ( mutated bases are in bold ) and produced PGS5456 . 
and aspects of the present disclosure and are not to be The second set of primers , 5 = GTCGGCTGCACGGCG 
construed as limiting the scope thereof . GTCGTCGGCGGCGTCGTGCACCGCCTCCTCGC 
CGCCTA CGGGCCCGGGCTGAGGATGACGACGA 
Example 1 TAAGTAGGG ( SEQ ID NO : 7 ) and 
25 5 = CGCGACGTCCGTGTAGGCGCGCACGTAGTCCA 
Crystal Structure of the Herpesvirus Inner Tegument Protein GCCCGGGCCCGTAGGCGGCG AGGAGGCGGTG 
UL37 CACCAACCAATTAACCAATTCTGATTAG ( SEQ ID 
Material and Methods NO : 8 ) , was used to generate the D79A / D81A / E82A muta 
Cloning . Plasmid pGS3610 encodes the PRV Becker tions , which were introduced into PGS5456 to produce the 
UL37 gene fused to an N - terminal Hish - SUMO tandem tag . 30 final mutant , pGS5476 . PRV - GS5476 typically propagated 
This was made by cutting the pETDuet - SUMO vector ( a to a titer of > 5x108 PFU / ml . The region 2 ( R2 ) and region 
derivative of pETDuet - 1 and a gift from Thomas Schwartz ) 3 ( R3 ) mutant viruses were produced in the same manner as 
and the pGS1740 subclone of UL37 with BamHI and the Ca mutant . For mutations were introduced into 
HindIII . The pJP4 plasmid , which contains a His6 - SUMO PGS4284 in three sequential rounds using primers 5 = -CTC 
PreScission tag in frame with the BamHI restriction site of 35 GACCACACGCAGGTGGACGCCACGGGCGT 
the multiple - cloning site in a pET24b vector , was made GTGGGAGGCGGTGGCGGCCAG CGCCTCGCCGAG 
through PCR of the His6 - SUMO - PreScission tag from pET GATGACGACGATAAGTAGGG ( SEQ ID NO : 9 ) and 
Duet - SUMO using the primers 5 = -GGGAATTC 5 = -CGCGGTCACGAGCGCCTCCACGACCTGCAGCG 
CATATGGGCAGCAGCCATCACCATCA ( SEQ ID NO : 1 ) GCGAGGCGCTGGCCGCCACCGC CTCCCACAC 
and 3 = -CTAGGGATCCGGGCCCCTGGAACAGAACTT 40 CAACCAATTAACCAATTCTGATTAG ( SEQ ID NO : 10 ) 
( SEQ ID NO : 2 ) . The PCR product was subcloned into ( encoding ( 324A ) , 5 = -GACCTCCTCGAGCGCGCCGT 
PET24b using Ndel and BamHI restriction sites . The PRV GCTGGACCGCGCGCCCCGCCTGACGGCCGCGCAG 
UL37 gene for Escherichia coli expression was synthesized GCTGCCGTCGGCTGCACGAGGATGACGACGA 
by GeneArt . The N - terminal half ( residues 1 to 496 ) of TAAGTAGGG ( SEQ ID NO : 11 ) and 5 = -GAGGCGGTG 
codon - optimized PRV UL37 ( referred to as UL37N ) was 45 CACGACGCCGCCGACGACCGCCGTGCAGCCGACG 
amplified by PCR from the full - length PRV codon - opti GCAGCCTGCGC 
mized UL37 gene using the primers 5 = -CTAGGGATC GGCCGTCAGGCGGGGCGCCAACCAATTAACCAAT 
CATGGAAGCACTGGTTCGTGC ( SEQ ID NO : 3 ) and TCTGATTAG ( SEQ ID NO : 12 ) ( encoding D362A / 
3 = -CTAGAAGCTTCTAGGCTGCGCTGGTCGGTG R365A ) , and 5 = -GGGGACGTGACGGCG 
( SEQ ID NO : 4 ) . The PCR product was subcloned into PJP4 50 GCGCTGGGGCTCCCCGAGAAGGGCGTGGAGGCCG 
using the BamHI and HindIII restriction sites to yield TGGT GCGCGCTTGCATGGCGCCGCGCAGGATGAC 
plasmid pJP23 . GACGATAAGTAGGG ( SEQ ID NO : 13 ) and 
Virus construction . All recombinant PRV ( strain Becker ) 5 = -GCGCGCCGCGCCCACGTGCTC 
isolates were derived from a variant of the pBecker3 infec CGTGGGCGGGCGCGGCGCCATGCAAGCGCGCAC 
tious clone , pGS4284 , that encodes the mCherry red fluo- 55 CACGGCCTCCACGCCCTTCTCCAACCAATTAAC 
rescent protein fused in frame to the UL25 capsid protein CAATTCTGATTAG ( SEQ ID NO : 14 ) ( encoding H421A / 
( Bohannon KP , Sollars P J , Pickard G E , Smith G A. 2012 . H425A ) . The first PCR product was recombined into 
Fusion of a fluorescent protein to the pUL25 minor capsid PGS4284 , resulting in PGS5483 . The second PCR product 
protein of pseudorabies virus allows live - cell capsid imaging was then recombined into PGS5483 , resulting in PGS5558 . 
with negligible impact on infection . J. Gen. Virol . 93 : 124- 60 The final recombination was made into PGS5558 , resulting 
129 ) . Viruses were produced by electroporation of infectious in PGS5604 . PRV - GS5604 typically propagated to a titer of 
clones into the pig kidney epithelial cell line PK15 , as > 5x108 PFU / ml . The R3 mutations were introduced in two 
previously described ( Luxton G W , Haverlock S , Coller KE , rounds using primers 5 = -CTGCCGCTGGCGTTGGCGGT 
Antinone S E , Pincetic A , Smith G A. 2005. Targeting of GCGCCAGATGCAGAACGAGGGCCTGGCGCAGCTG 
herpesvirus capsid transport in axons is coupled to associa- 65 ACGCGCGCGCTCAGGATGACGACGATAAGTAGGG 
tion with specific sets of tegument proteins . Proc . Natl . ( SEQ ID NO : 15 ) and 5 = -GAAGAACTCGTCGGC 
Acad . Sci . U.S.A. 102 : 5832-5837 ) . PK15 cells were main GATCGTGAGGGCAAAGAGCGCGCGCGTCAGCT 
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GCGCCA GGCCCTCGTTCTGCAACCAATTAACCAAT ments ) fitted with a CoolSnap HQ2 camera ( Photometrics ) . 
TCTGATTAG ( SEQ ID NO : 16 ) ( encoding D239A / E240A ) Two orthogonal diameter measurements of each fluorescent 
and primers 5 = AACCCGACGCTGCGCGAGCAGT plaque were obtained using the Metamorph software pack 
TCGCCGAGGCGGCGCGGGCCGTGGCCGCGG age ( Molecular Devices ) and averaged . The reported plaque 
CGGCGCTGGTGCCCAGGATGACGACGATAAG 5 diameters represented an average of more than 50 plaques 
TAGGG ( SEQ ID NO : 17 ) and 5 = -CGTGCGCGGCGTG per virus . Measurements of the plaque diameters of mutant 
GCGTTGACCTCGCCCACGGGCACCAGCGCCGC viruses were always conducted side by side with measure 
CGCGGCCAC ment of the plaque diameter of PRV - GS4284 ( the virus 
GGCCCGCGCCGCCAACCAATTAACCAATTCT encoding wild - type ( WT ) UL37 ) , and the diameters of the 
GATTAG ( SEQ ID NO : 18 ) ( encoding K203A / P204Q ) . The 10 mutant viruses were normalized to that diameter . Single - step 
first PCR product was recombined into PGS4284 , resulting growth and plaque diameters were plotted using the Prism 
in PGS5242 . The second PCR product was then recombined software package ( GraphPad Software ) . 
into PGS5242 , resulting in PGS5350 . PRV - GS5350 typically Virion protein incorporation . PK15 cells were infected with 
propagated to a titer of > 5x10 % PFU / ml . The region 1 ( R1 ) either PRV - GS4284 ( WT ) or PRV - GS604 ( R2 ) at an MOI of 
mutant virus ( V249R / R254A / R285A / D287A / H311A ) was 15 3. Infections were carried out in 15 - cm dishes of confluent 
generated using a modified two - step recombination . The cells . Infected cells and extracellular media were harvested 
region of the UL37 gene encoding amino acids 249 to 311 once all cells displayed a cytopathic effect , which was 
was first replaced with the kanamycin resistance cassette of typically at 18 hpi . Cellular debris was removed by cen 
PEPkan - S using primers 5 = -CCGAGGCGGCGCGGGC trifugation at 5,000xg , and virions were concentrated from 
CGTGGACGAGGCGGCGCTGGTGCCCGTGGGCGA 20 the supernatant by pelleting through a 10 % Nycodenz cush 
GACG CAGGTGGACGCCACGGGAGGATGACGAC ion at 13,000 rpm in an SW28 rotor ( Beckman ) . The 
GATAAGTAGGG ( SEQ ID NO : 19 ) and resulting pellet was resuspended in 100 ul of TNE buffer 
5 = -GAGGCGCTGGCCTGCACCGCCTCCCACACGC ( 150 mM NaCl , 50 mM Tris ( pH 7.4 ) , 10 mM EDTA ) . Viral 
CCGTGGCGTCCACCTGCGTCTCGC CCACGGGCAC particles were dispersed by 10 1 - s pulses of sonication in a 
CAGCGCAACCAATTAACCAATTCTGATTAG ( SEQ ID 25 cup horn ultrasonic processor ( VCX - 500 ; Sonics and Mate 
NO : 20 ) . The PCR product was recombined into PGS4284 , rials , Newtown , Conn . ) . The sample was loaded onto a 12 to 
resulting in the intermediate construct PGS5313 . The dele 32 % dextran gradient and centrifuged at 20,000 rpm for 1 h 
tion in PGS5313 was then repaired using a 489 - bp synthetic at 4 ° C. The heavy viral band was collected and spun at 
DNA encoding the missing UL37 sequence with the five 25,000 rpm in a Beckman SW50.1 rotor at 4 ° C. for 30 min . 
codon changes and 150 bp of flanking homologous sequence 30 The final pellet was resuspended in final sample buffer ( 10 
to each side ( pGS5267 ; Integrated DNA Technologies ) . The mM Tris [ pH 7.4 ) , 150 mM NaCl , 1 % Triton X - 100 ) 
synthetic DNA was released from a pIDTSmart vector using containing 10 % B - mercaptoethanol , and the samples were 
flanking HindIII sites and recombined into PGS5313 . boiled for 5 min prior to electrophoresis of 5 ul of each 
Recombination was carried out by growing E. coli strain sample through an 8 % sodium dodecyl sulfate ( SDS ) 
GS1783 harboring PGS5313 in 30 ml of Luria Broth ( LB ) 35 polyacrylamide gel . Proteins were subsequently transferred 
supplemented with 20 ug / ml chloramphenicol to an optical onto an Immobilon polyvinylidene difluoride membrane 
density at 600 nm ( OD600 ) of 0.6 at 32 ° C. in a baffled flask . ( Millipore ) , and VP5 was detected using the 3C10 mouse 
At this point , 20 ml of LB supplemented with 20 ug / ml monoclonal antibody ( a gift of Lynn Enquist ) at a 1 : 1,000 
chloramphenicol and 2 % L - arabinose was added , and the dilution . UL37 was detected using D1789 , a rabbit antise 
culture was incubated with shaking at 32 ° C. for 70 min . The 40 rum raised against a peptide derived from the PRV UL37 
culture was then transferred to a 42 ° C. shaking water bath sequence ( REAADRVLGDYHE ) , at a 1 : 2,500 dilution . The 
for 15 min , and the contents were then transferred to a 50 - ml secondary goat antimouse and antirabbit dye - labeled anti 
conical tube and chilled on ice . The chilled bacteria were bodies ( LiCor ) were used at 1 : 5,000 dilutions . Proteins were 
washed three times , and the final pellet was suspended in visualized and quantitated using an Odyssey Fc imager and 
300 ml double - distilled H20 , of which 48 ul was used in an 45 ImageStudio software ( LiCor ) . The ratio of UL37 to VP5 
electroporation with 2 ul of the pGS5267 synthetic frag was quantified for four independent experiments and nor 
ment . After recovery , the reaction mixture was plated on LB malized to the average value obtained for the UL37 - to - VP5 
agar plates supplemented with 20 ug / ml chloramphenicol ratio for WT virus . Data were plotted using the Prism 
and 2 % L - arabinose . The resulting isolate was saved as software package ( GraphPad Software ) , and significance 
PGS5321 . PRV - GS5321 typically propagated to a titer of 50 was determined using an unpaired Student's t test . 
> 5x10?PFU / ml . The sequences of all genetic modifications Protein expression and purification . Both UL37 and UL37N 
in the infectious clones were confirmed . constructs were expressed as N - terminal Hish - SUMO 
Viral propagation kinetics , viral titers , and plaque size fusions in T7 Express E. coli ( New England BioLabs ) . 
analysis . Quantitation of viral propagation kinetics was Freshly transformed cells were incubated at 37 ° C. overnight 
assessed by single - step growth in PK15 cells infected at a 55 in 5 ml LB starter culture supplemented with 50 ug / ml 
multiplicity of infection ( MOI ) of 10 for each viral stain . kanamycin . The starter culture was diluted into 1 liter LB 
Viral titers from cells or medium supernatants harvested at supplemented with 50 ug / ml kanamycin and grown at 37 ° C. 
2 , 5 , 8 , 12 , or 24 h postinfection ( hpi ) were determined in until the OD600 reached 0.8 to 1.0 . At this point , the 
duplicate by plaque assay , as previously described ( Smith G temperature was shifted to 16 ° C. and the cells were induced 
A , Enquist L W. 1999. Construction and transposon muta- 60 with 0.5 mM isopropyl - b - D - thiogalactopyranoside ( IPTG ) . 
genesis in Escherichia coli of a full - length infectious clone For production of UL37N , expression was induced for 16 to 
of pseudorabies virus , an alphaherpesvirus . J. Virol . 20 h . Cells were harvested by centrifugation at 12,000xg for 
73 : 6405-6414 ) . Measurements of plaque diameters were 40 min , resuspended in 25 ml 20 mM piperazine - N , N = -bis 
obtained by infection of PK15 cells in 6 - well trays with ( 2 - ethanesulfonic acid ) ( PIPES ) , pH 7.0 , 50 mM NaCl , 0.1 % 
serial 10 - fold dilutions for each virus . At 4 days postinfec- 65 Igepal CA - 630 ( Sigma ) , 5 % glycerol , 10 mM imidazole , 
tion , images were captured with a X4 objective on a Nikon 0.1mM tris ( 2 - carboxyethyl ) phosphine ( TCEP ) , and 1 EDTA 
TE2000 inverted fluorescence microscopy ( Nikon Instru free complete protease inhibitor cocktail tablet ( Roche ) , and 
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lysed by use of a French press . The insoluble fraction was Mass spectrometry . For mass spectrometry analysis , the 
removed by centrifugation of the whole - cell lysate at UL37 protein was analyzed using sinapinic acid ( Agilent 
14,000xg for 30 min at 4 ° C. Soluble lysate was loaded onto Technologies ) as the matrix . Mass spectrometry measure 
a 5 - ml Ni - Sepharose 6B FF column ( GE Healthcare ) . The ments were performed on a Voyager DE - Pro matrix - assisted 
column was subsequently washed with 10 column volumes 5 laser desorption ionization — time of flight mass spectrom 
( CVs ) of 20 mM PIPES , PH 7.0 , 50 mM NaCl , 0.1 mM eter ( Applied Biosystems ) . 
TCEP ( buffer A ) containing increasing amounts of imida Crystallization and structure determination . Crystals of 
zole at 10 mM or 25 mM . Protein was eluted in buffer A UL37N were grown by vapor diffusion at room temperature 
containing 100 mM imidazole . The eluate was immediately in hanging drops using 1 ul protein and 1 ul well solution 
concentrated , and the imidazole was removed by buffer 10 containing 24 to 26 % polyethylene glycol 1000 , 0.3MCa 
exchange into buffer A using an Ultra - 15 50 - kDa - cutoff ( CH3COO ) 2 , and 0.1M imidazole , pH 8.0 . Large plates 
concentrator ( Millipore ) . The protein concentration was formed in 3 to 8 days and were harvested 2 to 4 weeks later . 
determined from the absorbance at 280 nm using a calcu For data collection , crystals were incubated in a solution 
lated extinction coefficient . Glutathione S - transferase identical to the well solution plus 10 % glycerol for 30 s to 
( GST ) -tagged PreScission protease was added to the protein 15 2 min prior to flash freezing in liquid N2 . Heavy atom 
solution at a 1:50 protease - to - protein ratio , and the protein derivative crystals were obtained by soaking native crystals 
was cleaved overnight at 4 ° C. to remove the His6 - SUMO in well solution containing 5 mM thimerosal ( Na salt of 
tag . The protease - protein solution was sequentially applied ethylmercurithiosalicylic acid or C , H , HgNaO , S ) for 12 to 
to glutathione - Sepharose 4B ( GE Healthcare ) and Ni -Sep 16 h . Derivative crystals were harvested and frozen using the 
harose 6B to remove the GST - tagged PreScission protease 20 protocol developed for the native crystals . X - ray diffraction 
and the His6 - SUMO tag , respectively . Cleaved protein was data were collected at 100 K at the X25 beam line at the 
present in the unbound and wash fractions . UL37N was National Synchrotron Light Source . The data were pro 
further purified by size exclusion chromatography using a cessed using HKL2000 ( Otwinowski Z , Minor W. 1997 . 
Superdex 200 column ( GE Healthcare ) and concentrated to Processing of X - ray diffraction data collected in oscillation 
3.5 to 4.0 mg / ml using an Ultra - 15 30 - kDa - cutoff concen- 25 mode . Methods Enzymol . 276 : 307-326 ) and indexed in 
trator ( Millipore ) . space group P21 ( Table 1 ) . The native data set was processed 
Protein purity was assessed by SDS - polyacrylamide gel up to a 2.0 - Å resolution , and the single - wavelength anoma 
electrophoresis ( PAGE ) and Coomassie G - 250 staining . The lous dispersion ( SAD ) Hg data set was processed to a 2.3 - Å 
final yield was 18 mg of pure protein per 1 liter of E. coli resolution ( Table 1 ) . All 12 heavy atom sites were found 
culture . All UL37N protein samples used for crystallization 30 using the phenix.autosol program , and the experimental 
and biochemical studies were stored in 20 mM PIPES , PH density allowed the tracing of ~ 70 % of the residues in the 
7.0 , 50 mM NaCl , and 0.5 mM TCEP . phenix.autobuild program . Additional residues were manu 
A BL2 1 E. coli strain expressing GST - tagged PreScission ally built using the Coot program ( Emsley P , Cowtan K. 
protease was a gift from Peter Cherepanov ( London 2004. Coot : model - building tools for molecular graphics . 
Research Institute , London , United Kingdom ) . Protein 35 Acta Crystallogr . D Biol . Crystallogr . 60 : 2126-2132 ) . There 
expression was induced with 0.5 mM IPTG at 30 ° C. for 4 are two UL37N molecules in the asymmetric unit . 
h before the cells were harvested and lysed . The PreScission Before refinement of the heavy atom model , 10 % of the 
protease was purified over glutathione - Sepharose in a buffer data was set aside for cross - validation . The model was 
containing 20 mM Tris , pH 8.0 , 200 mM NaCl , and 1 mM refined against the SAD Hg data set to 2.3 - Å resolution 
TCEP . The column was washed 3 times with 10 CVs of the 40 using the phenix.refine program . Next , test set flags were 
binding buffer , and protein was eluted from the column in transferred to the native data set ; additionally , 10 % of the 
binding buffer containing 5 mM reduced glutathione . The native data between 2.3 and 2.0 Å was set aside for cross 
eluted protein was concentrated in a 30 - kDa - cutoff concen validation . After several cycles of refinement in the 
trator ( Millipore ) and further purified over a Superdex 200 phenix.refine program ( Adams PD , Grosse - Kunstleve R W , 
size exclusion column equilibrated with the binding buffer . 45 Hung L W , loerger T R , McCoy AJ , Moriarty N W , Read R 
The protein was concentrated to 1 mg / ml , flash frozen , and J , Sacchettini J C , Sauter N K , Terwilliger T C. 2002 . 
stored at -80 ° C. PHENIX : building new software for automated crystallo 
Thermofluor assay . The optimal buffer composition and graphic structure determination . Acta Crystallogr . D Biol . 
the optimal NaCl concentration for the stability of the Crystallogr . 58 : 1948-1954 ) and rebuilding in Coot ( Emsley 
UL37N protein ( PIPES , pH 7.0 , and 50 mM NaCl ) were 50 et al , supra ) , Rwork was 17.3 % and Rfree was 22.0 % . The 
determined using the Thermofluor method ( 34 ) . Protein was final model contained all amino acids from residues 1 to 479 , 
diluted to 0.15 mg / ml in the storage buffer , and a fluorescent including 3 of the 4 linker residues left after protease 
dye , SYPRO orange ( Invitrogen ) , was added at a 1 : 1,000 cleavage of the N - terminal tag . The final model is missing 
dilution . Ten microliters of the protein - dye solution was residues 480 to 496 in both chains . The MolProbity server 
pipetted into each well of a 96 - well PCR microplate . Next , 55 ( Davis I W , Leaver - Fay A , Chen V B , Block J N , Kapral G 
10 ul of buffer ( from a custom - made screen containing J , Wang X , Murray L W , Arendall W B , III , Snoeyink J , 
buffers at pH 4.5 to 10.5 and NaCl concentrations ranging Richardson J S , Richardson D C. 2007. MolProbity : all 
from 0 to 500 mM ) was added to wells containing the atom contacts and structure validation for proteins and 
protein dye solution . The plate was sealed and centrifuged nucleic acids . Nucleic Acids Res . 35 : W375 - W383 ) was used 
for 1 min at 500xg and 25 ° C. Samples were analyzed on a 60 to assess the stereochemical quality of all models . According 
Roche LightCycler 480 quantitative PCR machine using an to MolProbity , 99.0 % of the residues lie in the most favored 
excitation wavelength of 465 nm and detection of emission regions of the Ramachandran plot and 1 % lie in the addi 
at 610 nm . The emission signal was analyzed from 25 ° C. to tionally allowed regions of the Ramachandran plot . Final 
95 ° C. at a continuous acquisition rate of 3 measurements statistics are listed in Table 1 . 
per ° C. Data were analyzed using the ThermoQ software 65 Structure analysis . The sequence alignment was generated 
program . Conditions that stabilized UL37N further and analyzed using the Clustal W ( Larkin MA , Blackshields 
increased its solubility . G , Brown N P , Chenna R , McGettigan P A , McWilliam H , 
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Valentin F , Wallace I M , Wilm A , Lopez R , Thompson JD , to n3 ) . Linker residues GS , which precede the start methio 
Gibson T J , Higgins D G. 2007. Clustal W and Clustal X nine , form the N terminus of helix al . Hairpins 1 through 3 
version 2.0 . Bioinformatics 23 : 2947-2948 ) and ESPRIPT form a helical stack ( FIG . 1E ) . Hairpin 1 consists of two 
( Gouet P , Courcelle E , Stuart D I , Metoz F. 1999. ESPript : short antiparallel helices , while hairpin 2 consists of two 
analysis of multiple sequence alignments in PostScript . 5 longer kinked helices , and hairpin 3 has two up helices 
Bioinformatics 15 : 305-308 ) programs . Interfaces were ana followed by a loop and a single down helix . Helix n1 
lyzed using the PISA program ( Krissinel E , Henrick K. connects hairpins 2 and 3. The last two helices , a23 and 
2007. Inference of macromolecular assemblies from crys a24 , form hairpin 5 ( FIG . 1E ) . Only the top part of hairpin 
talline state . J. Mol . Biol . 372 : 774-797 ) . Structural homol 5 interacts with hairpins 1 to 3 , an arrangement that results 
ogy searches were performed using the Dali server ( Holm L , 10 in a large U - shaped groove within domain I. Hairpin 4 , 
Rosenstrom P. 2010. Dali server : conservation mapping in formed by helix a 10 running antiparallel to helices a9 and 
3D . Nucleic Acids Res . 38 : W545 - W549 ) , and the top hits m2 , forms a plug in the U - shaped groove in domain I. Helix 
were superposed onto the UL37N protein using the Dalilite m3 forms the tip of the plug . At the opposite end of the plug , 
pairwise comparison tool . The Evolutionary Trace server a solitary helix , a8 , at the tip of a long extension interacts 
was used for evolutionary trace analysis . All structure fig- 15 with domain II . 
ures were made in the PyMOL program . The Dali structural homology search ( Holm et al . , supra ) 
Protein structure accession number . Atomic coordinates revealed that domain I bears a structural resemblance to the 
and structure factors for the UL37N structure have been helical bundle domains of several subunits of multisubunit 
deposited in the RCSB Protein Data Bank under accession tethering complexes . Conserved residue W477 plays a key 
number 4K70 . 20 role in the stability of not only domain I but also the entire 
Results UL37N because a shorter construct , UL37N from residues 1 
Characterization of UL37N . Initially , full - length PRV to 476 [ UL37N ( 1 to 476 ) ] , which lacks residue W477 , has 
UL37 was expressed with an N - terminal His6 - SUMO tag in a lower thermal stability and progressively loses secondary 
E. coli ( FIG . 1A ) . During expression , this protein underwent structure during storage ( FIG . 2 ) . W477 helps anchor the 
spontaneous proteolysis , which generated a fragment con- 25 hairpin 4 plug in domain I through van der Waals interac 
taining the Hish - SUMO tag and the N terminus of UL37 tions with several hydrophobic residues and a hydrogen 
( FIG . 1B ) . Using mass spectrometry , the proteolytic site was bond with the carboxyl of D169 ( FIG . 1D ) , as well as van 
localized around residue 498 , which is approximately in the der Waals interactions with several hydrophobic residues in 
middle of the UL37 sequence . The difficulty in separating domain III . Domain II , residues 185 to 295 , consists of 
full - length UL37 from the truncated UL37 resulted in a very 30 helices all to al4 and two 310 helices ( n4 and 45 ) ( FIG . 
low yield of the purified full - length UL37 , --200 ug / liter cell 1E ) . Helices all to a13 form a helical bundle , in which the 
culture . Unlike full - length UL37 , which was prone to aggre last turn of helix al2 adopts a u - helix conformation . The 
gation , the N - terminal product of proteolytic cleavage was putative nuclear export signal ( NES ) , residues 263 to 273 in 
readily soluble and was pursued further . A fragment con HSV - 2 ( Watanabe D , Ushijima Y , Goshima F , Takakuwa H , 
taining residues 1 to 496 of UL37 ( UL37N ) plus an N - ter- 35 Tomita Y , Nishiyama Y. 2000. Identification of nuclear 
minal His6 - SUMO tag was expressed in E. coli ( FIG . 1A ) , export signal in UL37 protein of herpes simplex virus type 
purified to homogeneity , and the Hish - SUMO tag was 2. Biochem . Biophys . Res . Commun . 276 : 1248-1254 ) , maps 
cleaved ( FIG . 1B ) , obtaining a yield of ~ 18 to 20 mg per liter to buried helix a12 ( FIG . 1E ) and is unlikely to be func 
of cell culture . The optimal buffer composition and NaCl tional . Two long loops at the bottom of domain II are well 
concentration for protein stability , PIPES , PH7.0 , and 50 40 structured ( FIG . 1E ) and adopt similar conformations in the 
mM NaCl , were determined using the Thermofluor method . two UL37N molecules present within the crystal asymmetric 
These conditions further increased the solubility of UL37N . unit . Helix a14 appears to buttress both loops . Domain II 
All UL37N protein samples used for crystallization and does not have any structural homologs according to the Dali 
biochemical studies were stored in 20 mM PIPES , PH 7.0 , server ( Holm et al . , supra ) . Domain III , residues 296 to 431 , 
50 mM NaCl , and 0.5 mM TCEP . 45 is composed of helices a15 to a22 and one 310 helix ( 76 ) 
Architecture of UL37N . The crystal structure of UL37N ( FIG . 1E ) . This domain is also a helical bundle , with the a19 
was determined using single anomalous dispersion and central helix surrounded by the other six helices . This central 
refined against a 2.0 - Å native data set ( Table 1 ) . There are helix maintains the structural integrity of domain III and is 
two monomers in the asymmetric unit , and the final model highly conserved . 
included residues 1 to 479 plus N - terminal linker residues 50 UL37N is a dimer in crystals but a monomer in solution . 
PGS in both monomers ( Table 1 ) . The two monomers Two UL37N monomers in the asymmetric unit form an 
adopted very similar conformations , with the root mean X - shaped dimer ( FIG . 3A ) that buries 1,734.8 Å2 of surface 
square deviation ( RMSD ) being 0.4 for 482 common C - a area . Four calcium ions are coordinated at the dimer inter 
residues ( Holm et al . , supra ) . UL37N is an elongated mol face as two symmetry related sets of two calcium ions . Each 
ecule with dimensions of 99 by 42 by 26 Å composed of 24 55 set is coordinated by carboxyl oxygens from the side chains 
a helices and 6 310 helices arranged into a series of helical of Asp79 , Asp81 , and Glu82 of one monomer , carboxyl 
bundles ( FIG . 1C ) . The structure can be divided into three oxygens from the side chains of Asp382 and Asp383 plus the 
domains : domain I , residues 1 to 184 and 432 to 479 ; domain carbonyl oxygen of Trp379 of the other monomer , and two 
II , residues 185 to 295 ; and domain III , residues 296 to 431 water molecules ( FIG . 3B ) . As a result , one calcium ion is 
( FIG . 1C and E ) . 60 hexahedrally coordinated , while the second is pentahedrally 
Domain I is formed by two noncontiguous segments of coordinated . 
the polypeptide chain , residues 1 to 184 and residues 432 to Despite forming a dimer in crystals , UL37N is a monomer 
479 ( FIG . 1E ) . Residue 479 is the last resolved residue ; no in solution . Crystal formation required the presence of at 
electron density was observed for residues 480 to 496 , and least 0.1M Ca ( CH3COO ) 2 , and the best crystals were 
they are likely disordered . Domain I consists of five helical 65 obtained in the presence of 0.3MCa ( CH2COO ) 2 . In solution , 
hairpins with the up - down topology which are formed by UL37N remained monomeric even in the presence of 
12a helices ( al to al0 , 223 , and a24 ) and 3 310 helices ( n1 0.2MCaCl2 , judging by its elution volume on size exclusion 
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chromatography ( FIG . 3C ) . It was concluded that the V249R / R254A / R285A / D287A / H311A ( R1 mutant ) , 
dimerization of UL37N observed in crystals is likely Q324A / D362A / R365A / H421A / H425A ( R2 mutant ) , and 
induced by crystallization conditions ( a high protein con K203A / P204Q / D239A / E240A / D295A ( R3 mutant ) ( FIG . 
centration and the presence of calcium ) . The coordination of 5C ) . Mutated residues define three regions of potential 
four calcium ions at the dimer interface helps explain the 5 functional importance , referred to as regions 1 through 3 ( R1 
importance of calcium ions in mediating crystal contacts . In to R3 , respectively ) . R1 and R3 are located in domain II of 
the absence of calcium , the buried interface would have been UL37N , and R2 is located in domain III of UL37N . Addi 
smaller , 1,504.0 Å2 instead of 1,734.8 Å2 . Although UL37N tionally , residues involved in calcium binding were mutated 
does not dimerize in solution , the dimerization interface to confirm that potential calcium - induced dimerization of 
features multiple grooves and several negatively charged 10 UL37 is not essential for function , generating the mutant 
patches ( FIG . 3D ) . In full - length UL37 , this area may D79A / D81A / E82A / D382A / D383A ( Ca ) . 
participate in intramolecular contacts with the C - terminal UL37 region 2 is required for efficient viral spread . All 
half of UL37 , which is also conserved among alphaherpes mutations were introduced into the PRV strain Becker 
viruses and is predicted to be largely a helical . background , and each virus was propagated to wild - type 
ETA reveals several conserved surface clusters within 15 titers . To further investigate these mutants , viral replication 
UL37N . To analyze sequence conservation within UL37N , and spread were measured in single - step growth and plaque 
a sequence alignment of 15 UL37 homologs from alphaher formation assays , respectively . The Ca , R1 , and R3 mutants 
pesviruses , a subfamily of herpesviruses that includes HSV did not display any reduction in plaque size or viral repli 
and PRV , was generated . Thirty five strictly conserved cation . In contrast , the R2 mutant plaques were restricted to 
residues ( FIG . 4 ) were identified . Most are located within 20 about half the diameter of virus encoding wild - type UL37 
the hydrophobic core and are used for maintaining the ( FIG . 7A ) . A defect in plaque formation can be the result of 
structural integrity of the protein , vbut 11 of these conserved a defect in cell - cell spread or propagation kinetics . To 
residues are surface exposed ( FIGS . 3 and 5A ) and are a address this question , the rates of cell - associated virus 
logical choice for mutational analysis because surface - ex production and virus release into the supernatant were 
posed conserved residues often participate in protein - protein 25 measured . The amount of virus released into the supernatant 
interactions . None of these , however , clustered in a way that by the UL37 R2 mutant virus was similar to the amount 
would help pinpoint regions of potential functional impor released by the WT virus , indicating that the R2 mutations 
tance ( FIG . 5A ) . cause a defect in cell - cell spread ( FIG . 7B ) . There was no 
To locate potentially important functional sites on the reduction in the structural incorporation of the UL37 R2 
surface of UL37N , ETA ( 43 ) was performed on the same 30 mutant protein relative to that of wild - type UL37 on the 
sequence alignment ( FIG . 6 ) . ETA uses a sequence align basis of immune detection in purified extracellular virions 
ment of homologous proteins to generate a phylogenetic ( FIG . 7C ) . In fact , the R2 mutant protein was slightly 
tree , which is then broken up into partitions , with more increased in virions relative to the amount of wild - type 
closely related sequences being grouped into classes . Within UL37 ( 161 % ; n 4 ) , but this was not statistically significant . 
each partition , consensus sequences are generated for each 35 It is contemplated that the R2 cluster serves as a binding site 
set of sequences within a class . Each position within the for as of yet unidentified cellular or viral proteins important 
sequence alignment is designated conserved , class specific , for UL37 function in virus trafficking , which is essential in 
or neutral . Conserved residues have the same residue in all cell - cell spread . 
consensus sequences , whereas class - specific residues have a UL37 shares structural similarity with subunits of the 
common residue for each closely related subgroup , but that 40 CATCHR family of tethering complexes . The UL37 proteins 
residue is different among more divergent subgroups . Posi have no notable sequence homology to any viral or host 
tions lacking consensus among the members of at least one proteins . 
subgroup are considered neutral . Clustering of conserved A Dali search ( Holm et al . , supra ) revealed that domain I 
and class - specific residues on the protein surface may indi resembles several subunits of eukaryotic multisubunit teth 
cate regions of potential functional importance ( Lichtarge O , 45 ering complexes ( MTCs ) ( Jackson L P , Kummel D , Reinisch 
Bourne H R , Cohen F E. 1996. An evolutionary trace KM , Owen D J. 2012. Structures and mechanisms of vesicle 
method defines binding surfaces common to protein fami coat components and multi subunit tethering complexes . 
lies . J. Mol . Biol . 257 : 342-358 ) . This method has been used Curr . Opin . Cell Biol . 24 : 475-483 ; Brocker C , Engelbrecht 
to detect functional sites in a number of proteins ( Sowa M Vandre S , Ungermann C. 2010. Multi subunit tethering 
E , He W , Slep KC , Kercher MA , Lichtarge O , Wensel TG . 50 complexes and their role in membrane fusion . Curr . Biol . 20 : 
2001. Prediction and confirmation of a site critical for R943 - R952 ) . In intracellular trafficking pathways , MTCs 
effector regulation of RGS domain activity . Nat . Struct . Biol . tether vesicles to the target organelles to which they localize 
8 : 234-237 ; Chakravarty S , Hutson A M , Estes M K , Prasad both to bring the vesicles closer to their target membranes 
B V. 2005. Evolutionary trace residues in noroviruses : and to help ensure the delivery of the vesicle to the correct 
importance in receptor binding , antigenicity , virion assem- 55 target organelle ( Brocker et al . , supra ) . Several subunits of 
bly , and strain diversity . J. Virol . 79 : 554-568 ) . four MTCs , the Dsl 1 complex , the exocyst complex , the 
ETA on UL37N revealed several surface clusters which Golgi - associated retrograde protein ( GARP ) complex , and 
contained both conserved and class - specific residues ( FIG . the conserved oligomeric Golgi protein ( COG ) complex , 
5A and B ) . Several of these were not considered further share strong structural similarities , despite low sequence 
because they either contained salt bridges , which are likely 60 identity ( Jackson et al . , supra ; Richardson B C , Smith RD , 
essential for protein stability alone , or contained several Ungar D , Nakamura A , Jeffrey PD , Lupashin V V , Hughson 
residues with only partially exposed side chains . Three F M. 2009. Structural basis for a human glycosylation 
clusters were chosen for further analysis . To probe their disorder caused by mutation of the COG4 gene . Proc . Natl . 
functional roles , 4 to 5 residues within each cluster were Acad . Sci . U.S.A. 106 : 13329-13334 ; Tripathi A , Ren Y , 
mutated to either eliminate a bulky side chain or , in two 65 Jeffrey P D , Hughson F M. 2009. Structural characterization 
cases , to replace a small side chain with a bulky one . Three of Tip20p and Dsllp , subunits of the Dsllp vesicle tethering 
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galung A H , Fu C , Novick P , Reinisch K M. 2005. The TABLE 1 - continued 
structures of exocyst subunit Exo70p and the Exo84p C - ter 
Data collection and refinement statistics minal domains reveal a common motif . Nat . Struct . Mol . 
Biol . 12 : 1094-1100 ) , a finding which points to their common Value for : 
evolutionary origin and mechanistic similarities . Their struc 
Native crystal tures consist of one to five helical bundle domains of similar Native crystal soaked in thimerosal folds . UL37N shares the highest structural similarity with 
several subunits of the Dsll complex and the exocyst , with No. of atoms 7,983 
Protein 7,342 Dali Z - scores of 4.2 to 5.4 ( FIG . 8 and Table 2 ) , while 10 Ligand / ion similarity to other MTC subunits is less pronounced . 
Although these similarity scores for the top hits are modest , B - factors 35.05 
they are comparable to the scores for some of the more Protein Ligand / ion distantly related MTC subunits . The structural similarity to Water MTC subunits is particularly remarkable because the RMSD 
sequence identity is under 10 % ( Holm et al . , supra ) . 
Residues 1 to 136 of domain I resemble the helical Bond length ( 8 ) 
Bond angle ( 0 ) bundles of MTCs the most and typically align with domain 
C of MTCs ( Jackson et al . , supra ) , but the structural simi " Values in parentheses are for the highest - resolution shell . 
larity between UL37N and MTCs extends beyond domain I bB - factor , isotropic displacement parameter . 
and includes domain II ( FIG . 8A ) . The domain I and domain 
II module resembles domains C , D , and E of MTC subunits 
TABLE 2 and has an overall J shape ( FIG . 8A ) , which is found in some 
tethering subunits as the result of an additional domain E Alignments of UL37N with components of MTCsa 
that follows domains C and D. Although the tip of domain 
II of UL37N only remotely resembles domain E of MTC No. of aligned residues % identity 
subunits , the folds of domain E diverge even among MTC Tip20 5.4 ( 3.8 ) 10.1 ( 3.8 ) 186 ( 92 ) 4 ( 14 ) subunits themselves ( FIG . 8A ) . The Cog4 subunit of the 5.0 ( 5.1 ) 3.9 ( 3.7 ) 145 ( 111 ) 7 ( 8 ) COG tethering complex has a salt bridge between domains 4.4 ( 5.8 ) 15.7 ( 3.3 ) 182 ( 123 ) 6 ( 9 ) 
4.2 ( 5.7 ) 11.1 ( 3.8 ) 159 ( 98 ) 6 ( 7 ) D and E that involves a conserved arginine ( 48 ) . UL37N also 
3.6 ( 3.8 ) 4.7 ( 4.6 ) 135 ( 107 ) 10 ( 10 ) has a salt bridge between D216 and R260 in subdomains 3.2 ( 4.4 ) 3.4 ( 3.5 ) 72 ( 97 ) 4 ( 4 ) II - D and II - E , respectively ( FIG . 8C ) , that is strictly con Exo84 2.5 ( 5.4 ) 4.1 ( 4.0 ) 75 ( 102 ) 4 ( 9 ) served among alphaherpesviruses ( FIG . 4 ) . Despite notice 
able similarity , the structure of UL37N differs from the All alignments were carried out using the Dali server ( 42 ) . Either the entire UL37N or just the helical bundle from residues 1 to 136 ( for which the data are given in parentheses ) was structures of MTC subunits in several aspects . First , instead 
of multiple helical bundles of similar topology ( 51 ) , it has 
only one helical bundle with a topology similar to the Example 2 topologies found in MTC subunits . Second , unlike in MTC 
subunits , where domain D or E is C terminal , the polypep A Surface - exposed Region of the UL37 Protein that is tide chain in UL37N continues into domain III and a hairpin 40 Essential for Alphaherpesvirus Neuroinvasion in domain I. Thus , the structural resemblance of domains I Alphaherpesviruses are pathogens that proficiently invade and II of UL37N to the MTCs may be the result of the peripheral nervous system of their host . Although infec convergent evolution . tions are not typically associated with significant symptoms , 
debilitating diseases including shingles , encephalitis and TABLE 1 45 blindness can arise from the active replication of these 
Data collection and refinement statistics viruses coupled with their ability to spread within neural 
circuits ( Levitz R E. Herpes simplex encephalitis : A review . 
Value for : Heart Lung . 1998 May - June ; 27 ( 3 ) : 209-12 ; Lichtarge O , 
Native crystal Bourne H R , Cohen F E. An evolutionary trace method 
Native crystal soaked in thimerosal 50 defines binding surfaces common to protein families . J Mol 
Biol . 1996 Mar 29 ; 257 ( 2 ) : 342-58 ) . Unfortunately , the viral Data collection factors that contribute to neuroinvasion remain largely 
Space group P21 unknown . Transport of herpesvirus capsids from the cell 
Unit cell dimensions periphery to the nucleus is useful for viral replication . In 
55 neuronal cells this distance often spans the length of the 
51.67 , 156.59 , 67.38 51.53 , 156.30 , 66.34 axon , eliminating passive diffusion as a viable means of A , B , Y O 90 , 91.33 , 90 90 , 91.78 , 90 
Resolution ( 8 ) 43.12-2.00 ( 2.07-2.00 ) 48.91-2.05 ( 2.12-2.05 ) delivery . The UL37 protein is a member of a small subset of 
Rzym or Rmerge 0.086 ( 0.516 ) 0.097 ( 0.280 ) viral proteins that remain associated with capsids as they 
20.32 ( 2.74 ) 13.87 ( 2.18 ) travel down the axon towards the nucleus to begin replica Completeness ( % ) 89.4 ( 49.5 ) 85.1 ( 35.31 ) 60 tion ( Schmitz J B , Albright A G , Kinchington P R , Jenkins Redundancy 6.3 ( 4.4 ) 3.9 ( 2.1 ) F J. The UL37 protein of herpes simplex virus type 1 is Refinement statistics 
associated with the tegument of purified virions . Virology . 
Resolution range 43.12-2.00 1995 February 1 ; 206 ( 2 ) : 1055-65 ) . Viruses deficient in this ( Å ) protein either fail to propagate or demonstrate delays in No. of reflections 64,342 ( 2,347 ) 
( free ) 65 transport of capsids to the nucleus prior to replication and in 
Rwork / R free morphogenesis post - replication ( Desai P , Sexton GL , 
McCaffery J M , Person S. A null mutation in the gene 




a , b , c ( Å ) 
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US 10,647,964 B2 
31 32 
encoding the herpes simplex virus type 1 UL37 polypeptide both a RFP - tagged R2 mutant ( R2 ) and a GFP - tagged 
abrogates virus maturation . J Virol . 2001 Nov ; 75 ( 21 ) : wild - type ( WT ) virus . Mid segments of axons were imaged 
10259-71 ; Klupp B G , Granzow H , Mundt E , Mettenleiter T during the first hour post infection ( hpi ) . The frequency of 
C. Pseudorabies virus UL37 gene product is involved in axon transport is reported as the average number of capsids 
secondary envelopment . J Virol . 2001 October ; 75 ( 19 ) : 8927- 5 entering the field of view per minute ( error bars = SEM ) . 
36 ; Krautwald M , Fuchs W , Klupp B G , Mettenleiter T C. FIG . 10 shows that R2 mutant particles display aberrant 
Translocation of incoming pseudorabies virus capsids to the non - processive motion . DRG explants were cultures as 
cell nucleus is delayed in the absence of tegument protein described in FIG.9 . FIG . 10A shows that mutation of the R2 
PUL37 . J Virol . 2009 April ; 83 ( 7 ) : 3389-96 ) . This supports an region significantly increases the severity of stop and rever 
essential role for UL37 in the intracellular transport of 10 sal events . Explants were infected were infected with 7.0x 
capsids during infection . A UL37N crystal structure ( UL37N 10 ? PFU / coverslip of either WT or R2 mutant virus and 
is the amino terminal half of the protein ) identified three imaged at 3.5 hpi . Kymographs were generated using the 
conserved surface - exposed regions ( Pitts J D , Klabis J , Metamorph software package . Entire particle paths , whether 
Richards A L , Smith G A , Heldwein E E. Crystal structure moving , stalled , or reversing , were traced within the kymo 
of the herpesvirus inner segument protein UL37 supports its 15 graph using the “ Multi - line ” tool . Fraction of time stopped 
essential role in control of viral trafficking . J Virol . 2014 and faction of time anterograde were calculated for each 
May ; 88 ( 10 ) : 5462-73 ) . The data demonstrated that pseudora particle by dividing the total time the particle was either 
bies virus ( PRV ) mutated in one of these regions , designated stopped or moving in the anterograde direction by the total 
R2 , is ablated in a critical neuroinvasion property : retro time the particle was imaged . Greater than 30 particles were 
grade axon transport . Although R2 mutant particles fuse 20 analyzed per virus for three replicate experiments and an 
with the axon plasma membrane to release the viral capsid , average value calculated for each virus . Values reported 
these capsids are defective at initiating long distance retro represent the mean of the average values obtained . ( error 
grade axon transport towards the nucleus to begin genome bars = SEM ) . FIG . 9B shows that aberrant motion of R2 
replication . Despite this dramatic neural defect , the R2 mutant particles does not result in overall movement 
mutant propagates with wild - type kinetics in epithelial cells 25 towards the soma . The average net displacement of all 
( Pitts et al . , supra ) . UL37 performs effector functions that moving virus particles over a 10 second period was calcu 
are required specifically during neural delivery . The UL37 lated . Inset image is a montage of six frames from a 
R2 region is essential for long distance retrograde motion in subregion of a time - lapse recording of the R2 mutant . Each 
both in vivo and in vitro systems R2 mutant particles exhibit frame is a 100 ms exposure representing every fifteenth 
short non - processive motion in axons The non - processive 30 frame of the original recording ( the montage represents a 7.5 
movement of R2 mutant particles is not the result of reten s time window ) . Retrograde motion of the particle is indi 
tion of envelope or outer tegument proteins following fusion cated with a red arrow while anterograde motion is shown 
with the cell membrane with a white arrow ( error bars = SEM ) . 
Results are shown in FIGS . 9-12 . FIG . 9 shows charac FIG . 11 shows that motion of R2 particles does not result 
terization of the neuroinvasive properties of the R2 mutant . 35 from endocytosis of virions or retention of outer tegument 
As shown in FIG.9A , the R2 region is essential for virulence proteins following entry . Fusion of extracellular enveloped 
in a mouse model of infection . CD - 1 mice were infected by virions with the plasma membrane results in separation of 
intranasal instillation of either wild - type ( WT ) PRV or PRV the viral capsid from the envelope and the majority of 
carrying mutations in the R1 , R2 , or R3 regions of the amino tegument proteins . To examine the role of the R2 region in 
terminal portion of the UL37 protein . Mice infected with the 40 these events a R2 mutant virus was generated with RFP 
R2 mutant did not present any symptoms of infection and fused to the capsid and GFP fused to either the gD envelope 
were sacrificed at 240 hpi . A total of five mice were infected protein or the VP13 / 14 or VP22 tegument proteins . These 
for each virus tested . “ dual - fluorescent ” viruses allow for monitoring of capsid 
FIG . 9B shows that the R2 region is essential for retro entry and tegument disassociation as determined by loss of 
grade mediated neuroinvasion . The eye anterior chamber of 45 the GFP signal . DRG explants were cultured as described in 
Long - Evans rats was injected with wild - type ( WT ) or R2 FIG . 9. Explants were infected were infected with 7.0x107 
mutant PRV encoding a fluorescent reporter . In this model , PFU / coverslip of the appropriate R2 mutant virus and 
wild - type PRV initially replicates in the iris and ciliary body imaged at 3.5 hpi . FIG . 11A shows that moving particles are 
then invades autonomic nerve endings to spread by retro not associated with the gD envelope protein or the outer 
grade axon transport to the superior cervical ganglion 50 tegument proteins VP22 and VP13 / 14 . Moving particles 
( SCG ) . By 48 hpi the wild - type PRV was detectd in neurons were scored as either “ Naked capsids ” : capsids lacking 
in the SCG , Following infection with the R2 mutant virus coincident GFP signal or as being associated with the 
was not observed in the SCG , images were taked at 120 hpi . respective GFP tagged protein gD ( envelope ) , VP13 / 14 , or 
FIG . 9C shows that the R2 region is dispensable for antero VP22 . Moving particles were defined as those that trav 
grade spread through neurons . For imaging of anterograde 55 eled > 2.5 um . Particles were tallied across two independent 
circuits virus was injected into the vitreous humor of the eye experiments with greater then three fields imaged per experi 
of the rat , which exposes the soma of retinal ganglion ( RG ) ment . The fraction of the total number of moving particles 
neurons to the inoculum . RG neurons project axons to the that were positive for either only the RFP signal or both the 
lateral geniculate nucleus ( LGN ) and superior colliculus RFP and GFP signals was calculated ( error bars = SEM ) . FIG . 
( SC ) therefore invasion of the LGN and SC by anterograde 60 11B shows that non - moving particles are predominantly 
trasport can be observed during infection . The R2 mutant associated with envelope and tegument proteins . As 
was detected in both the SC and the LGN at 102 hpi . FIG . described in panel ( A ) non - moving particles were scored as 
9D shows That the R2 mutant does not travel retrograde either “ Naked capsids " : capsids lacking coincident GFP 
down axons upon infection . Dorsal root ganglion ( DRG ) signal or as being associated with the respective GFP tagged 
sensory neurons were isolated from embryonic chickens 65 protein . Particles were tallied across two independent 
( embryonic day 8 [ E8 ] to E10 ) . Explants were cultured for experiments with greater then three fields imaged per experi 
three days prior to infection with 3.5x107 PFU / coverslip of ment . The fraction of the total number of non - moving 
15 
25 
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particles that were positive for either only the RFP signal or PRV mutants with the above mutations were engineered 
both the RFP and GFP signals was calculated ( error ( PRV - R2 ) . FIG . 13 shows that PRV R2 lacks neuroinvasive 
bars = SEM ) . properties . Mice were exposed to either wild type PRV ( WT ) 
FIG . 12 shows modeling of wild - type and the R2 mutant or the PRV UL37 R2 mutant ( R2 ) by eye injection , and 
trafficking in neuronal cells . The top view shows that 5 neuroinvasion was assessed by isolating the superior cervi 
herpesvirus replication occurs in the nucleus , this requires cal ganglion ( SCG ) that innervates the iris . Virus activity 
incoming particles to traverse the cytoplasm following entry marked by glowing neurons in the WT infection are absent 
into the cell . Wild - type virions fuse with the axon plasma in the R2 infection . 
membrane , which results in release of the capsid into the FIG . 14 shows that PRV R2 is avirulent . Groups of five 
cell . Capsids travel along axonal microtubules towards the 10 mice were infected with either wild - type PRV ( WT ) or PRV 
nucleus within the soma of the neuron ( Sodeik B , Ebersold mutated in one of the UL37 surface regions . The region 2 
MW , Helenius A. Microtubule - mediated transport of incom ( R2 ) mutant strain of PRV was avirulent . The mice infected 
ing herpes simplex virus 1 capsids to the nucleus . J Cell with R2 displayed no symptoms or weight loss during the 
Biol . 1997 March 10 ; 136 ( 5 ) : 1007-21 ) . The bottom view course of the experiment . 
shows that R2 mutant virions fuse with the plasma mem FIG . 15 shows that PRV R2 is a potent live - attenuated 
brane of the axon however the released capsids alternate vaccine . Four mice were administered the PRV R2 neuro 
between motion towards ( retrograde ) and away ( antero invasive mutant on day 1 ( x - axis ) . The weight of the animals 
grade ) from the soma . This “ non - processive ” motion pre in grams ( y - axis ) was monitored daily . On day 14 , the 
vents particles from reaching the soma to begin replication . animals received a lethal challenge of wild - type PRV ( blue 
20 vertical line ) . The red vertical line indicates the maximum 
Example 3 life - expectancy for unvaccinated animals . All four test ani 
mals survived to day 35 with only minimal fluctuations in 
Non - neuroinvasive Herpesviruses for Vaccine and Onco weight . 
lytic Vector Applications 
This example describes a conserved feature in herpesvi Example 4 
ruses that , when mutated , eliminates the neuroinvasive prop 
erty of the virus . This allows for the production of live Non - invasive Herpes Simplex Virus 
attenuated vaccine strains that lack the neuroinvasive A herpes simplex virus type 1 ( HSV - 1 ) non - invasive 
property , thereby preventing the establishment of life - long mutant encoding five codon changes in the R2 effector 
infections while retaining the ability of the virus to replicate 30 region of the pUL37 tegument protein : Q403A , E452A , 
and spread in peripheral tissues to generate a robust steril Q455A , Q511A , R515A was engineered . 
izing immune response . The HSV - 1 PUL37 R2 mutant ( HSV1 - GS6298 ) was con 
Three conserved surface regions in the UL37 tegument firmed unable to enter the peripheral ( trigeminal ganglion ) 
protein were observed when the three dimensional structure and central ( brain stem ) nervous system of mice following 
of this protein was determined ( Pitts et al . , supra ) . Mutation 35 inoculation into the periphery ( eye ; corneal scarification 
of one of these regions ( region 2 ) reduced the capacity of model ) ( FIG . 16 ) . In addition , the R2 mutant also displayed 
PRV to spread in epithelial cells , but did not impact its attenuated spread in the cornea . 
replication . The R2 mutagenesis method results in HSV - 1 lacking 
The important feature of the UL37 R2 mutants described neuroinvasive properties , consistent with our original find 
herein is robust infection at the peripheral site of inoculation 40 ings with PRV . This documents that a live - attenuated non 
to produce a robust immune response and immune memory , invasive vaccine strain of HSV - 1 is useuful . Furthermore , 
with no involvement of the nervous system ( which prevents the neuroinvasive effector function of R2 is conserved in 
establishment of life - long latent infections and subsequent PRV and HSV - 1 , which is consistent with R2 functional 
complications ) . conservation across the neuroinvasive herpesviruses given 
Identifying the sites to mutate in related viruses ( such as 45 that the R2 sequence is conserved . Therefore , live - attenu 
HSV and VZV ) was a two step process . First , the crystal ated non - invasive vaccines of clinically- and agriculturally 
structure of PRV UL37 ( Example 1 ) was used as a base relevant herpesvirus are produced using this technology 
model to map out the corresponding amino acids from the ( e.g. , varicella - zoster virus , bovine herpesvirus , equine her 
other viruses ( homology modeling and structure model pesvirus ) . 
analysis ) . Second , the relevance of the positions was con 
firmed based on primary sequence alignments . Example 5 
The mutations that destroy neuroinvasive properties are 
generally conserved in all alpha herpesviruses , but are R2 Mutation Design for Increased Safety 
unique to each virus ( Table 3 ) . To simplify the production and stabilize R2 mutants , a 55 new mutation design was developed based on an in - frame 
deletion and insertion of a 10 aa linker coding sequence TABLE 3 ( linker sequence : GSGSGSGSGS ( SEQ ID NO : 21 ) ) . The 
Mutations to eliminate the virus neuroinvasive properties linker was designed to span the cleft resulting from the 
deleted R2 region and thereby maintain proper folding of the Human pathogens 60 PUL37 protein , based on predictions made from PUL37 
Herpes simplex virus Q403A / E452A / Q455A / Q511A / R515A structural data . Mutants of HSV - 1 and PRV were produced , 
types 1 & 2 and the latter was tested in a vaccine model ( FIG . 17 ) . 
Q363A / D413A / Q416A / Q472A / R476A An improved non - invasive design intended to prevent Veterinary pathogens spontaneous reversion of the vaccine strain is able to protect 
Pseudorabies virus Q324A / D362A / R365A / H421A / H425A 65 mice from lethal PRV challenge . 
All publications , patents , patent applications and acces 
sion numbers mentioned in the above specification are 
50 
Varicella zoster virus 
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herein incorporated by reference in their entirety . Although embodiments . Indeed , various modifications and variations 
the disclosure has been described in connection with specific of the described compositions and methods of the disclosure 
embodiments , it should be understood that the disclosure as will be apparent to those of ordinary skill in the art and are 
claimed should not be unduly limited to such specific intended to be within the scope of the following claims . 
SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 36 
< 210 > SEQ ID NO 1 
< 211 > LENGTH : 34 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 1 
gggaattcca tatgggcagc agccatcacc atca 34 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 30 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 2 
ttcaagacaa ggtccccggg cctagggatc 30 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 30 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 3 
ctagggatcc atggaagcac tggttcgtgc 30 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 29 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 4 
gtggctggcg cgtcggatct tcgaagatc 29 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 94 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 5 
ctcgccgaga acctggccgg cctggcgctg tggcgcctgc gccacgcctg ggccgcgggc 60 
acggccccgc tgaggatgac gacgataagt aggg 94 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 97 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 6 
US 10.647.964 B2 
37 38 
- continued 
gtcgccgttg acgaccccca ggagctccag cagcggggcc gtgcccgcgg cccaggcgtg 60 
gcgcaggcgc cacaaccaat taaccaattc tgattag 97 
< 210 > SEQ ID NO 7 
< 211 > LENGTH : 88 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 7 
gtcggctgca cggcggtcgt cggcggcgtc gtgcaccgcc tcctcgccgc ctacgggccc 60 
gggctgagga tgacgacgat aagtaggg 88 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 91 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 8 
cgcgacgtcc gtgtaggcgc gcacgtagtc cagcccgggc ccgtaggcgg cgaggaggcg 60 
gtgcaccaac caattaacca attctgatta g 91 
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 85 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 9 
ctcgaccaca cgcaggtgga cgccacgggc gtgtgggagg cggtggcggc cagcgcctcg 60 
ccgaggatga cgacgataag taggg 85 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 88 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 10 
cgcggtcacg agcgcctcca cgacctgcag cggcgaggcg ctggccgcca ccgcctccca 60 
caccaaccaattaaccaatt ctgattag 88 
< 210 > SEQ ID NO 11 
< 211 > LENGTH : 94 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 11 
gacctcctcg agcgcgccgt gctggaccgc gcgccccgcc tgacggccgc gcaggctgcc 60 
gtcggctgca cgaggatgac gacgataagt aggg 94 
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 97 
< 212 > TYPE : DNA 
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- continued 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 12 
gaggcggtgc acgacgccgc cgacgaccgc cgtgcagccg acggcagcct gcgcggccgt 60 
caggcggggc gccaaccaat taaccaattc tgattag 97 
< 210 > SEQ ID NO 13 
< 211 > LENGTH : 97 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 13 
ggggacgtga cggcggcgct ggggctcccc gagaagggcg tggaggccgt ggtgcgcgct 60 
tocatggcgc cgcgcaggat gacgacgata agtaggg 97 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 100 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 14 
gcgcgccgcg cccacgtgct ccgtgggcgg gcgcggcgcc atgcaagcgc gcaccacggc 60 
ctccacgccc ttctccaacc aattaaccaa ttctgattag 100 
< 210 > SEQ ID NO 15 
< 211 > LENGTH : 88 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 15 
ctgccgctgg cgttggcggt gcgccagatg cagaacgagg gcctggcgca gctgacgcgc 60 
gcgctcagga tgacgacgat aagtaggg 88 
< 210 > SEQ ID NO 16 
< 211 > LENGTH : 91 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 16 
gaagaactcgtcggcgatcg tgagggcaaa gagcgcgcgc gtcagctgcg ccaggccctc 60 
gttctgcaac caattaacca attctgatta g 91 
< 210 > SEQ ID NO 17 
< 211 > LENGTH : 88 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 17 
aacccgacgc tgcgcgagca gttcgccgag gcggcgcggg ccgtggccgc ggcggcgctg 60 
gtgcccagga tgacgacgat aagtaggg 88 
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- continued 
< 210 > SEQ ID NO 18 
< 211 > LENGTH : 91 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 18 
cgtgcgcggc gtggcgttga cctcgcccac gggcaccagc gccgccgcgg ccacggcccg 60 
cgccgccaac caattaacca attctgatta g 91 
< 210 > SEQ ID NO 19 
< 211 > LENGTH : 92 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 19 
ccgaggcggc gcgggccgtg gacgaggcgg cgctggtgcc cgtgggcgag acgcaggtgg 50 
acgccacggg aggatgacga cgataagtag gg 92 
< 210 > SEQ ID NO 20 
< 211 > LENGTH : 95 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : DNA Primer 
< 400 > SEQUENCE : 20 
gaggcgctgg cctgcaccgc ctcccacacg cccgtggcgt ccacctgcgt ctcgcccacg 60 
ggcaccagcg caaccaatta accaattctg attag 95 
< 210 > SEQ ID NO 21 
< 211 > LENGTH : 10 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Linker sequence 
< 400 > SEQUENCE : 21 
gsgsgsgsgs 10 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 424 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 22 
Met Glu Ala Leu Val Arg Ala Leu Glu Glu Ala Asp His Ala Val Ala 
1 5 10 15 
Thr Val Val Gin Ser Arg Ile Leu Glu Phe Phe Met Ala Ala Gly Arg 
20 25 30 
Glu Thr Pro Ala Gly Val Arg Gly Leu Trp Ala Arg Ala Leu Arg Leu 
35 40 45 
Ala Cys Arg Ala Tyr Val Glu Thr Gly Thr Cys Glu Ala Ala Val Leu 
50 55 60 
Ala Glu Asn Leu Ala Gly Leu Ala Leu Trp Arg Leu Arg His Asp Trp 
65 70 75 80 
Asp Glu Gly Thr Ala Pro Leu Leu Glu Leu Leu Gly Val Val Asn Gly 
US 10,647,964 B2 
43 44 
- continued 
85 90 95 
Asp Asp Thr Thr Ala Ala Leu Thr Glu Ala Gly Leu Arg Thr Ser Ala 
100 105 110 
Glu Phe Gly Pro Asp Ala Met Phe Arg Leu Val Ser Glu Trp Cys Ala 
115 120 125 
Ala Phe Asp Glu Ala Leu Ala Gly Ala Arg Ser Ala Asp Asp Val Leu 
130 135 140 
Ala Ala Pro Arg Val Val Pro Pro Glu Gin Thr Ala Arg Ala Leu Val 
145 150 155 160 
Gin Pro Arg Phe Ala Thr Leu Tyr Asp Met Asp Phe Val Gin Asp Gly 
165 170 175 
Leu Arg Tyr Val Ala Gln His Thr Asn Trp Ala Leu Pro Leu Ala Leu 
180 185 190 
Ala Val Arg Gln Met Gin Asn Glu Gly Leu Lys Pro Leu Thr Arg Ala 
195 200 205 
Leu Phe Ala His Gly Asp Ala Tyr Val Arg Glu Leu Arg Pro Gly Thr 
210 215 220 
Val Ala Arg Arg Leu Arg Thr Asp Gin Gly Val Leu Ala Leu Leu Asp 
225 230 235 240 
Pro Gly Ala Gln Ala Val His Val Ala Ala Ala Ala Asp Leu Asp His 
245 250 255 
Thr Gin Val Asp Ala Thr Gly Val Trp Glu Ala Val Gin Ala Ser Ala 
260 265 270 
Ser Pro Leu Gin Val Val Glu Ala Leu Val Thr Ala Gly Phe Thr Arg 
275 280 285 
Arg His Cys Asp Leu Leu Glu Arg Ala Val Leu Asp Arg Ala Pro Arg 
290 295 300 
Leu Thr Asp Ala Gln Arg Ala Val Gly Cys Thr Ala Val Val Gly Gly 
305 310 315 320 
Val Val His Arg Leu Leu Asp Asp Tyr Gly Pro Gly Leu Asp Tyr Val 
325 330 335 
Arg Ala Tyr Thr Asp Val Ala Asp Thr Leu Glu Pro Leu Tyr Gly Asp 
340 345 350 
Val Thr Ala Ala Leu Gly Leu Pro Glu Lys Gly Val Glu His Val Val 
355 360 365 
Arg His Cys Met Ala Pro Arg Pro Pro Thr Glu His Val Gly Ala Ala 
370 375 380 
Arg Ala Ala Leu Leu Arg Glu Val Ala Ala Ala Glu Arg Arg Ala Gly 
385 390 395 400 
Leu Ala His Ser Ala Ala Arg Glu Ala Leu Asn Thr Trp Leu Ala Phe 
405 410 415 
Arg Ala Gin Ser Arg Trp Gly Leu 
420 
< 210 > SEQ ID NO 23 
< 211 > LENGTH : 537 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Bovine herpesvirus 
< 400 > SEQUENCE : 23 
Met Ser Gly Asp Pro Val Arg Ala Leu Trp Ala Ala Leu Glu Arg Leu 
1 5 10 15 
Asp Gly Glu Val Ala Gly Pro Ala Ala Leu Ala Glu Ala Arg Ala Ala 
20 25 30 
US 10,647,964 B2 
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Val Ser Glu Phe Leu Leu Ala Ser Gly Pro Ser Ser Leu Asp Phe Val 
35 40 45 
Ala Pro Arg Trp Ala Ala Leu Gin Arg Ala Ala Cys Arg Ala Tyr Glu 
50 55 60 
Arg Leu His Thr Pro Asp Ala Ala Leu Leu Ala Glu Asn Leu Pro Gly 
65 70 75 80 
Leu Val Leu Trp Arg Leu Pro Gly Ala Ala Arg Asp Thr Ala Asp Phe 
85 90 95 
Met Ala Gly Val Arg Asp Leu Ala Asn Ser Met Ile Ala Glu Ala Pro 
100 105 110 
Leu Gly Tyr Leu Ala Ala Ala Arg Leu Arg Ala Thr Ala Ala Phe Gly 
115 120 125 
Pro Val Asn Met Gln Arg Val Val Val Glu Trp Ala Ser Leu Phe Leu 
130 135 140 
Glu Ile Tyr Ala Arg Glu Asp Ala Ala Cys Val Gly Val Leu Gly Pro 
145 150 155 160 
Asp Pro Ala Cys Arg Ser Pro Ala Gly Ser Ala Ala Val Ile Arg Pro 
165 170 175 
Leu Leu Gln Ser Arg Phe Arg Leu Leu Tyr Asp Met Pro Phe Phe Gln 
180 185 190 
Ala Gly Leu Ser Ala Leu Ala His Ala Ala Asn Trp Lys Val Pro Met 
195 200 205 
Ala Ala Val Ala Arg Arg Ala Ala Asp Ala Ala Ala Pro Pro Leu Ala 
210 215 220 
Arg Ala Leu Phe Ala Val Ala Leu Val Asp Glu Tyr Phe Pro Glu Pro 
225 230 235 240 
Asp Asp Glu Asp Thr Ala Pro Gly Leu Ala Glu Ala Phe Ala Glu Ile 
245 250 255 
Ala Asp Leu Val Pro Pro Glu Ala Leu Val Pro Ala Gly Glu Ala Asn 
260 265 270 
Ala Phe Ala Arg Ser Ser His Asp Val Arg Val Ser Ala Ala Leu Ala 
275 280 285 
Tyr Arg Asp Pro Phe Val Arg Gly Ala Ala Ala Gly Ser Val Ala Ala 
290 295 300 
Arg Val Arg Ala Asp Ala Gly Leu Leu Ala Asp Asp Thr Leu Leu Gly 
305 310 315 320 
Arg Asp Ala Val Ala Val His Ala Gly Ala Val Val Arg Leu Leu Glu 
325 330 335 
Arg Ala Ala Ala Arg Ala Thr Pro Ala Ala Leu Gly Arg Val Ala Glu 
340 345 350 
His Ala Ala Ala Val Trp Asp Ala Val Gin Ala Ser Ala Thr Pro Asp 
355 360 365 
Gln Ala Val Glu Thr Leu Ala Ala Ala Gly Phe Thr Pro Gly Thr Cys 
370 375 380 
Ala Met Leu Glu Arg Ala Val Leu Ala Gln Leu Ser Arg Pro Glu Pro 
385 390 395 400 
Arg Ala Pro Ala Asp Val Leu Gln Ala Val Gly Cys Val Ala Val Ala 
405 410 415 
Gly Gly Val Leu Phe Lys Leu Phe Asp Ala Tyr Gly Pro Ser Ala Asp 
420 425 430 
Tyr Leu Ala His Tyr Thr Ala Thr Ile Ala Asn Leu His Pro Tyr Tyr 
435 440 445 
Ala Asp Val Leu Pro Leu Leu Gly Leu Pro Asp Gly Gly Leu Glu Gin 
US 10,647,964 B2 
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450 455 460 
Thr Ile Arg His Cys Met Ala Pro Arg Pro Arg Thr Asp Tyr Val Ala 
465 470 475 480 
Ala Ile Arg Ala Ala Leu Ala Ala Glu Ala Ala Ala Ala Asp Lys Arg 
485 490 495 
Ala Ala Ser Ala Ser Ala Arg Ala Ala Val Glu Asn Ser Gly Asp Arg 
500 505 510 
Ala Ala Ala Gly Ala Ala Ala Arg Glu Ala Leu Leu Thr Trp Phe Asp 
515 520 525 
Leu Arg Ala Ser Glu Arg Trp Gly Val 
530 535 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 541 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Equine herpesvirus 
< 400 > SEQUENCE : 24 
Met Ala Arg Glu Asp Trp Ser Met Arg Ala Leu Val Asn Thr Leu Ala 
1 5 10 15 
Gly Leu Leu Gly Glu Thr Asp Thr Asp Val Thr Ser Met Glu Pro Ala 
20 25 30 
Met Leu Met Val Leu Lys Ser Ser Ile Ser Glu Phe Phe Leu Ser Thr 
35 40 45 
Asp Thr Val Ser Val Glu Glu Ala Ala Glu Leu Phe Pro Arg Leu Gln 
50 55 60 
Phe Leu Ala Cys Arg Ala Tyr Ala Ala Ser His Thr Pro Glu Ala Ala 
65 70 75 80 
Met Leu Ala Glu Asn Leu Ser Gly Leu Val Leu Trp Arg Ile His Gin 
85 90 95 
Asn Trp Thr Asp Arg Glu Thr Glu Ala Val Asp Gin Met Phe Val Leu 
100 105 110 
Leu Glu Ile Met Asn Gly Glu Ser Gly Val Tyr Met Leu Ser Asn Asn 
115 120 125 
Asn Leu Arg Ile Ser Ala Lys Tyr Gly Pro Ser Asn Met His Leu Met 
130 135 140 
Val Ser Thr Trp Leu Gly Thr Phe Arg Asn Val Met Leu Ser Ile Ala 
145 150 155 160 
Asn Thr Thr Pro Asp Ala Met Phe Asn Ala Arg Arg Ile Glu Ala Ile 
165 170 175 
Glu Glu Phe Ser Lys Pro Leu Val His Lys Arg Phe Asp Leu Ile Tyr 
180 185 190 
Asp Met Pro Phe Val Gin Glu Gly Leu Arg Ile Val Ala Ala Lys Ile 
195 200 205 
Asn Trp Leu Leu Pro Phe Gly Leu Ile Ala Lys Arg Ser Lys Asp Thr 
210 215 220 
Ser Met Ala Pro Leu Thr Arg Ala Leu Phe Leu Leu Ser Leu Val Asp 
225 230 235 240 
Ser Tyr Phe Pro Lys Gly Thr Ala Thr Asn Ser Ser Met Lys Ala Leu 
245 250 255 
Thr Ile Tyr Phe Arg Glu Ile Val Arg Asn Ile Asp Asn Ser Ala Phe 
260 265 270 
Val Pro Val Thr Glu Val Asn Ala Thr Pro Arg Thr Ala Tyr Glu Val 
275 280 285 
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Arg Val Ser Ser Ala Ile Val His Gin Asn Pro Tyr Val Thr Asp Thr 
290 295 300 
Lys Ala Gly Met Val Ala Glu Arg Val Arg Thr Asp Ala Glu Ile Leu 
305 310 315 320 
Ser Ser Gly Ala Leu Leu Ser Ser Gly Ala Leu Ser Ala His Val Thr 
325 330 335 
Ala Val Ala Lys Leu Leu Ala Phe Asn Asp Gln Asn Asp Thr Ser Ser 
340 345 350 
Val Ala Arg Ala Arg Val Ala Glu His Ala Ser Asn Thr Trp Glu Ala 
355 360 365 
Ile Gin Ala Ser Thr Thr Pro Ala Gin Val Val Glu Ala Leu Val Thr 
370 375 380 
Ala Gly Phe Thr Ser Thr His Cys Gly Ile Leu Glu Arg Val Val Val 
385 390 395 400 
Asp Tyr Phe Thr Arg Leu Arg Ser Thr Ala Glu Ser Arg Pro Gly Gin 
405 410 415 
Asp Asn Ser Leu Asp Tyr Ala Gin Gin Val Val Gly Cys Val Ser Ile 
420 425 430 
Val Gly Gly Val Val Phe Arg Leu Leu Met Ser Tyr Gly Phe Gly Leu 
435 440 445 
Asp Tyr Ile Arg Asp Tyr Thr Thr Thr Ile Ser Thr Leu Glu Pro Val 
450 455 460 
Tyr Asn Glu Leu Leu Leu Ala Leu Gly Leu Ala Asp Lys Gly Val Glu 
465 470 475 480 
Gin Thr Leu Arg Arg Ser Met Ala Pro Arg Pro Tyr Met Asn Tyr Ile 
485 490 495 
Ser Ala Ala Arg Ala Ala Leu Asp Asn Glu Leu Leu Ile Val Glu Lys 
500 505 510 
Arg Thr Thr Gly Pro Gly Thr His Ser Ala Ala Arg Glu Ser Leu Leu 
515 520 525 
Thr Trp Phe Asp Phe Arg Ala Arg Asp Arg Trp Gly Val 
530 535 540 
< 210 > SEQ ID NO 25 
< 211 > LENGTH : 540 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 25 
Met Asp Asn Ser Gly Pro Leu Met Thr Leu Val Ala Ser Leu Glu Gly 
1 5 10 15 
Leu Val Gly Val Ala Ser Asp Arg Leu Thr Gin Asp Gly Val Leu Arg 
20 25 30 
Ile Lys Ser Met Ile Ser Glu Phe Phe Leu Ser Thr Asp Ser Ile Glu 
35 40 45 
Leu Arg Asp Thr Gin Arg Leu Trp Ala Lys Leu Gln Lys Leu Ala Cys 
50 55 60 
Asp Ala Tyr Leu His Thr Arg Ser Pro Glu Thr Ala Phe Leu Ala Glu 
65 70 75 80 
Asn Leu Pro Gly Leu Ile Phe Trp Arg Phe Lys His Asp Trp Thr Glu 
85 90 95 
Ser Pro Ile Asn Asp Leu Thr Asp Ile Ser Thr Leu Leu Asp Val Met 
100 105 110 
Asn Asp Glu Glu Cys Met Ala Cys Ile Thr Thr Ala Gly Leu Arg Val 
115 120 125 
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Ser Ser Phe Leu Gly Pro Ser Asn Ile Tyr Arg Leu Val Ser Glu Trp 
130 135 140 
Ile Val Leu Phe Lys Glu Ile Tyr Leu Gly Val Leu Asn Lys Thr Pro 
145 150 155 160 
Ser Asp Ala Leu Asn Glu Pro Pro Ile Ser Ser Leu Asp Lys Phe Ser 
165 170 175 
Glu Pro Leu Val Ser Lys Lys Phe Glu Leu Leu Tyr Gly Met Pro Phe 
180 185 190 
Val Gin Glu Gly Leu Arg Val Ile Ala Ile Arg Ala Asn Trp Leu Val 
195 200 205 
Gin Phe Gly Val Met Val Gin Arg Thr Arg Asp Ser Thr Leu Thr Pro 
210 215 220 
Leu Thr Arg Ala Leu Tyr Met Leu Ala Leu Val Asp Glu Tyr Phe Gin 
225 230 235 240 
Asp Ile Glu Gin Thr Ser Thr Tyr Thr Thr Leu Val Arg Asp Phe Leu 
245 250 255 
Glu Leu Thr Gin Glu Ile Asp Glu Gly Ala Leu Val Pro Leu Gln Ala 
260 265 270 
Ala Asn Leu Ser Pro Arg Thr Ala Tyr Glu Val Arg Ile Ser Ser Ala 
275 280 285 
Ile Ala His Gin Asn Pro Phe Ile Thr Asn Pro Gin Pro Gly Thr Val 
290 295 300 
Thr Val Arg Leu Arg Thr Asp Pro Glu Ile Leu Thr Glu Arg His Leu 
305 310 315 320 
Asn Leu Glu Ala Leu Leu Ile His Val Thr Ala Ile Ile Arg Leu Leu 
325 330 335 
Asp Ser Lys Asp Ile Thr Tyr Glu Asp Gly Ser Asn Thr Ile Trp Asn 
340 345 350 
Tyr Val Val Glu Cys Thr Thr Asn Thr Trp Glu Val Ile Gin Ala Ser 
355 360 365 
Thr Asn Pro His Gin Ala Ile Glu Ala Leu Ile Gin Ala Gly Phe Thr 
370 375 380 
Ser Phe His Cys Ser Met Leu Glu Arg Ala Ile Ser Asp Lys Phe Ser 
385 390 395 400 
Lys Ala Arg Ile Ser Asn Ile Asn Arg His Ser Ile Gin Arg Pro Leu 
405 410 415 
Leu Asp Glu Ala Gin Gin Ala Ile Gly Cys Val Ala Met Val Gly Ser 
420 425 430 
Leu Ile Phe Lys Leu Val Thr His Tyr Gly Asn Gly Leu Asp Tyr Ile 
435 440 445 
Arg His Tyr Thr Thr Thr Leu Ala Asp Leu Pro Leu Val Tyr Gly Asp 
450 455 460 
Leu Leu Asp Ser Leu Gly Leu Pro Asn Gly Ser Val Glu Gin Ile Ile 
465 470 475 480 
Arg His Cys Met Ala Pro Lys Pro Tyr Ile Asp Tyr Ile Thr Asn Ser 
485 490 495 
Arg Val Val Phe Glu Thr Glu Leu Asn Leu Val Asp Gin Arg Val Val 
500 505 510 
Thr Val Glu Gly Asn Thr His Asn Ala Ala Arg Glu Ser Leu Leu Met 
515 520 525 
Trp Phe Asp Phe Lys Ala Arg Asp Leu Trp Gly Ile 
530 535 540 
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< 210 > SEQ ID NO 26 
< 211 > LENGTH : 553 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 26 
Met Trp Phe Asp Val Phe Cys Ile Val His Pro Thr Val Asp Ile Met 
1 5 10 15 
Glu Thr Ala Ile Thr Gin Asn Leu Leu Asn Asp Leu Lys Ser Leu Ser 
20 25 30 
Ser Lys Asp Asp Ser Ser Glu Thr Ile Trp Pro Pro Glu Lys Val Glu 
35 40 45 
Thr Ala Arg Ile Ser Ile Val Lys Phe Leu Arg Ser Thr Gln Glu Ile 
50 55 60 
Pro Leu Glu Asn Thr Leu Trp Thr Glu Leu His Lys Val Ile Cys Asn 
65 70 75 80 
Val Tyr Ala His Thr Phe Leu Ile Glu Ala Ser Phe Leu Ala Glu Asn 
85 90 95 
Leu Pro Gly Leu Ile Phe Trp Lys Leu Glu Ser His Cys Thr Gln Asn 
100 105 110 
Val Met Gin His Met Glu Thr Leu Lys Gln Leu Cys Asn Asn Ile Gin 
115 120 125 
Ser Arg Glu Thr Leu Gin Arg Leu Thr Leu His Ser Leu Arg Thr Ser 
130 135 140 
Ala Lys Leu Gly Pro Val Ser Ile Asn Ser Leu Val Thr Asp Trp Ile 
145 150 155 160 
Asn Met Phe Glu Val Ala Val Arg Asp Ile Asn Glu Ala Thr Lys Leu 
165 170 175 
Pro Phe Leu Tyr Ala Arg Gin Gly Met Val Glu Ser Ala Val Ala Ala 
180 185 190 
Leu Thr His Gin Arg Phe Ala Leu Leu Tyr Asp Met Pro Ile Val Gin 
195 200 205 
Asp Gly Leu Arg Ile Leu Thr Gin Arg Ala Ser Trp Leu Ile Pro Phe 
210 215 220 
Thr Ile Met Trp Ser His Ile Gin Ser Asp Ser Phe Thr Pro Leu Thr 
225 230 235 240 
Lys Cys Leu Phe Ile Ile Asn Leu Ala Asp Glu Tyr Phe Asp Asp Thr 
245 250 255 
Pro Val Ser Tyr Leu Thr Asp Leu Phe Asn Asp Asn Ile Ile His Val 
260 265 270 
Lys Asp Ile Ala Phe Val Pro Ile Glu Glu Ala Ile Val Gin Ala Thr 
275 280 285 
Thr Val His Gly Ala Arg Ile Asn Ala Ala Leu Ala His Gln Asn Leu 
290 295 300 
Ser Ile Arg Gln Thr Gln Pro Gly Thr Ala Thr His Arg Leu Arg Val 
305 310 315 320 
Asp Val Asn Ile Trp Asp Asn Asn Ile Leu Ser Leu Ser Ala Pro Gly 
325 330 335 
Ile His Ile Asp Gly Leu Leu His Leu Ile Thr Thr Asp Pro Thr Ala 
340 345 350 
Glu Thr Thr Ala Gly Ala Ala Val Ala Glu Cys Val Arg Val Ala Trp 
355 360 365 
Glu Arg Val Gin Ala Ser Thr Ser Pro Asn Ser Leu Val Leu Ala Leu 
370 375 380 
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Leu Glu Ala Gly Phe Thr Arg Tyr Thr Cys Lys Leu Leu Arg Lys Phe 
385 390 395 400 
Val Thr His Cys Thr Leu Gly Leu His Ser Leu Tyr Asp Thr His Ile 
405 410 415 
Thr His Glu Val Cys Lys Leu Thr Asp Phe Gin Gin Thr Ile Gly Cys 
420 425 430 
Val Ser Leu Val Gly Gly Leu Ala Tyr Gin Leu Leu Glu Thr Tyr Ala 
435 440 445 
Pro Thr Ala His Tyr Val Ser Thr Tyr Thr His Ile Leu Ser Glu Thr 
450 455 460 
Glu Lys Arg Tyr Glu Thr Leu Ile Pro Ala Leu Gly Leu Pro Pro Gly 
465 470 475 480 
Gly Leu Gly Gin Ile Met Arg Arg Cys Phe Ala Pro Arg Pro Leu Ile 
485 490 495 
Ser Ser Ile Gin Leu Ala Arg Lys Thr Leu Val Glu Glu Ile Asn Thr 
500 505 510 
Ala Glu Thr Arg Lys Thr Val Leu His Leu Gin His Thr Arg Glu Thr 
515 520 525 
Gin Pro Gly Ala Arg Val Thr Arg Glu Ala Ile Leu Thr Trp Phe Asp 
530 535 540 
Phe Arg Met Glu Ser Arg Trp Gly Ile 
545 550 
< 210 > SEQ ID NO 27 
5211 > LENGTH : 547 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 27 
Met Glu Glu Pro Ile Cys Tyr Asp Thr Gin Lys Leu Leu Asp Asp Leu 
1 5 10 15 
Ser Asn Leu Lys Val Gin Glu Ala Asp Asn Glu Arg Pro Trp Ser Pro 
20 25 30 
Glu Lys Thr Glu Ile Ala Arg Val Lys Val Val Lys Phe Leu Arg Ser 
35 40 45 
Thr Gin Lys Ile Pro Ala Lys His Phe Ile Gln Ile Trp Glu Pro Leu 
50 55 60 
His Ser Asn Ile Cys Phe Val Tyr Ser Asn Thr Phe Leu Ala Glu Ala 
65 70 80 75 
Ala Phe Thr Ala Glu Asn Leu Pro Gly Leu Leu Phe Trp Arg Leu Asp 
85 90 95 
Leu Asp Trp Thr Ile Glu Glu Pro Gly Asn Ser Leu Lys Ile Leu Thr 
100 105 110 
Gin Leu Ser Ser Val Val Gin Asp Ser Glu Thr Leu His Arg Leu Ser 
115 120 125 
Ala Asn Lys Leu Arg Thr Ser Ser Lys Phe Gly Pro Val Ser Ile His 
130 135 140 
Phe Ile Ile Thr Asp Trp Ile Asn Met Tyr Glu Val Ala Leu Lys Asp 
145 150 155 160 
Ala Thr Thr Ala Ile Glu Ser Pro Phe Thr His Ala Arg Ile Gly Met 
165 170 175 
Leu Glu Ser Ala Ile Ala Ala Leu Thr Gln His Lys Phe Ala Ile Ile 
180 185 190 
Tyr Asp Met Pro Phe Val Gln Glu Gly Ile Arg Val Leu Thr Gln Tyr 
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195 200 205 
Ala Gly Trp Leu Leu Pro Phe Asn Val Met Trp Asn Gin Ile Gin Asn 
210 215 220 
Ser Ser Leu Thr Pro Leu Thr Arg Ala Leu Phe Ile Ile Cys Met Ile 
225 230 235 240 
Asp Glu Tyr Leu Thr Glu Thr Pro Val His Ser Ile Ser Glu Leu Phe 
245 250 255 
Ala Asp Thr Val Asn Leu Ile Lys Asp Glu Ala Phe Val Ser Ile Glu 
260 265 270 
Glu Ala Val Thr Asn Pro Arg Thr Val His Glu Ser Arg Ile Ser Ser 
275 280 285 
Ala Leu Ala Tyr Arg Asp Pro Tyr Val Phe Glu Thr Ser Pro Gly Met 
290 295 300 
Leu Ala Arg Arg Leu Arg Leu Asp Asn Gly Ile Trp Glu Ser Asn Leu 
305 310 315 320 
Leu Ser Leu Ser Thr Pro Gly Ile His Ile Glu Ala Leu Leu His Leu 
325 330 335 
Leu Asn Ser Asp Pro Glu Ala Glu Thr Thr Ser Gly Ser Asn Val Ala 
340 345 350 
Glu His Thr Arg Gly Ile Trp Glu Lys Val Gin Ala Ser Thr Ser Pro 
355 360 365 
Ser Met Leu Ile Ser Thr Leu Ala Glu Ser Gly Phe Thr Arg Phe Ser 
370 375 380 
Cys Lys Leu Leu Arg Arg Phe Ile Ala His His Thr Leu Ala Gly Phe 
385 390 395 400 
Ile His Gly Ser Val Val Ala Asp Glu His Ile Thr Asp Phe Gin Gin 
405 410 415 
Thr Leu Gly Cys Leu Ala Leu Val Gly Gly Leu Ala Tyr Gin Leu Val 
420 425 430 
Glu Thr Tyr Ala Pro Thr Thr Glu Tyr Val Leu Thr Tyr Thr Arg Thr 
435 440 445 
Val Asn Glu Thr Glu Lys Arg Tyr Glu Thr Leu Leu Pro Ala Leu Gly 
450 455 460 
Leu Pro Pro Gly Gly Leu Gly Gln Ile Met Arg Arg Cys Phe Ala Pro 
465 470 475 480 
Arg Pro Leu Ile Glu Ser Ile Gln Ala Thr Arg Val Ile Leu Leu Asn 
485 490 495 
Glu Ile Ser His Ala Glu Ala Arg Glu Thr Thr Tyr Phe Lys Gin Thr 
500 505 510 
His Asn Gln Ser Ser Gly Ala Leu Leu Pro Gin Ala Gly Gln Ser Ala 
515 520 525 
Val Arg Glu Ala Val Leu Thr Trp Phe Asp Leu Arg Met Asp Ser Arg 
530 535 540 
Trp Gly Ile 
545 
< 210 > SEQ ID NO 28 
< 211 > LENGTH : 545 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 28 
Met Ser Ala Val Thr Thr Asp Glu Ile Trp Pro Leu Lys Val Leu Leu 
1 5 10 15 
US 10,647,964 B2 
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Asp Thr Leu Arg Ser Leu Ser Ser Arg Thr Ser Pro Thr Glu Pro Trp 
20 25 30 
Gly Ala Thr Ala Thr Ala Glu Ala Arg Ala Ala Ile Gly Ser Phe Phe 
35 45 40 
Leu Ala Ser Gly Thr Met Ser Ile Leu Gin Val Glu Leu Thr Trp Arg 
50 55 60 
Asp Thr Phe Ser Ala Ile Leu Glu Val Tyr Lys Gin Thr Arg Ser Pro 
65 70 75 80 
Glu Ala Ser Met Leu Ala Gln Asn Phe Val Gly Leu Ile Leu Trp Arg 
85 90 95 
Ile Ser Val Arg Trp Asp Lys Thr Ser Trp Gin Glu Asn Ser His Arg 
100 105 110 
Leu Arg Arg Leu Val Ala Glu Met Thr Gly Glu Glu Ala Ile Ser Trp 
115 120 125 
Leu Ser Arg Asn Asn Leu Arg Ile Ser Ala Pro Phe Gly Pro Ser Val 
130 135 140 
Met Trp Pro Leu Ile Ser Glu Trp Phe Ala Val Phe Glu Asp Ala Ala 
145 150 155 160 
Asn His Ala Phe Thr Tyr Thr Pro Glu His Leu Leu Ser Glu Arg Glu 
165 170 175 
Phe Ser Phe Asn Val Gly Asp Leu Ala Ala Ser Leu Ala His Lys Arg 
180 185 190 
Phe Glu Leu Ile Tyr Asp Phe Pro Phe Val Gin Glu Gly Ile Arg Leu 
195 200 205 
Val Ser Ile Ala Ser Gly Trp Ile Ala Pro Phe Val Ile Met Tyr Arg 
210 215 220 
Cys Thr Thr Asn Arg Val Phe Thr Pro Leu Thr Arg Ile Leu Phe Thr 
225 230 235 240 
Ile Ala Leu Val Asp Gin Tyr Phe Arg Gly Leu His Ala Pro Gin Pro 
245 250 255 
Phe Gin Ile Lys Asp Arg Phe Ala Glu Asp Val Gly Ala Leu Gly Ser 
260 265 270 
Lys Glu Leu Ile Pro Ala Leu Glu Ala Asn Ser Thr Lys Arg Thr Ser 
275 280 285 
Tyr Glu Val Arg Ala Ser Ala Ala Ile Ala Tyr Glu Ser Pro Phe Val 
290 295 300 
His Thr Ile Gin Pro Gly Met Ala Ala Asp Lys Leu Arg Asn Gly Ser 
305 310 315 320 
Asp Ile Ile Met Ser Asp Thr Ser Leu Thr Glu Asp Ser Leu Ala Ile 
325 330 335 
His Leu Ser Ala Val Leu Arg Leu Ile Ser Asp Ile Gly Leu Glu Glu 
340 345 350 
Asp Asn Gly Ala Ile Asp Ala Ala Lys Ala Lys Leu Ser Asn Ser Ala 
355 360 365 
Arg Arg Ala Trp Asp Ala Ile Gin Tyr Ser Ser Ser Pro Lys Gin Leu 
370 375 380 
Leu Glu Ala Leu Ile Glu Arg Gly Phe Val Arg Gin Val Cys Arg Ala 
385 390 395 400 
Tyr Glu Ser Ala Leu Lys Thr Tyr Phe Thr Arg Asn Tyr Gly Ser Val 
405 410 415 
Asp Glu Gly Asp Ile Phe Asp Asp Val Gin Gin Val Val Gly Cys Val 
420 425 430 
Ala Val Ile Gly Asn Val Val Phe Gly Leu Ile Glu Ser Tyr Gly Pro 
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435 440 445 
Gly Met Thr Tyr Leu Ser Asn Tyr Met Glu Asn Cys Val Ile Ser Glu 
450 455 460 
Ser Asp Ser His Phe Ile Glu Ala Leu Gly Leu Glu Arg Ala Ile Ile 
465 470 475 480 
Ser Gin Ile Ile Gly Arg Cys Ile Pro Pro Ile Pro His Glu Asp Tyr 
485 490 495 
Ile Lys Ala Ala Arg Ala Val Leu Val Ala Glu Met Asp His Val Ala 
500 505 510 
Ser Lys Ser Glu Ala Val Gly Phe Arg Gln Ser Ile Arg Ser Ala Lys 
515 520 525 
Glu Ser Leu Met Leu Trp Phe Asp Asn Arg Ala Asn Glu Ile Trp Gly 
530 535 540 
Ile 
545 
< 210 > SEQ ID NO 29 
< 211 > LENGTH : 539 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 29 
Met Ser Glu Thr Gin Gly Glu Ala Arg Phe Pro Leu Lys Thr Leu Leu 
1 5 10 15 
Asp Thr Leu Arg Ser Leu Ser Ala Gly Thr Ala Pro Leu Glu Pro Trp 
20 25 30 
Gly Asn Ala Thr Ala Ala Glu Ala Arg Thr Ala Ile Gly Ser Phe Phe 
35 40 45 
Gln Ala Leu Glu Thr Met Ser Ile Gin Gin Val Glu Ser Thr Trp Arg 
50 55 60 
Asp Ala Phe Ala Ala Val Leu Glu Val Tyr Lys Gin Thr Gly Ser Pro 
65 70 75 80 
Glu Ala Ala Met Leu Ala Gln Asn Phe Val Gly Phe Ile Leu Trp Arg 
85 90 95 
Thr Ser Val Arg Trp Asp Lys Met Ser Trp Lys Asp Asp Ser Arg Arg 
100 105 110 
Leu Arg Arg Leu Ala Ala Glu Met Thr Gly Glu Glu Ala Ile Ala Trp 
115 120 125 
Leu Thr Arg Asn Gly Leu Arg Arg Ser Cys Pro Phe Gly Pro Ser Val 
130 135 140 
Leu Trp Pro Leu Ile Ser Glu Trp Leu Thr Ile Phe Glu Glu Ile Ala 
145 150 155 160 
Thr Asp Ala Phe Asp Tyr Thr Ser Glu Gly Leu Leu Ser Gly Arg Gin 
165 170 175 
Pro Ala Pro Asn Ala Leu Glu Leu Pro Ala Ser Leu Thr Gln Thr Arg 
180 185 190 
Phe Lys Leu Ile Tyr Asp Phe Pro Phe Val Gln Glu Gly Ile Arg Leu 
195 200 205 
Ile Ser Ile Ala Val Gly Trp Ile Thr Pro Phe Val Ile Met Ser Arg 
210 215 220 
Cys Thr Thr Asn Arg Ala Phe Thr Pro Leu Thr Arg Ile Leu Phe Thr 
225 230 235 240 
Leu Ala Leu Val Asp Gln Tyr Phe Lys Ser Pro Arg Ser Pro His Pro 
245 250 255 
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Ser Gin Leu Lys Asp Leu Phe Ala Glu Asp Ala Ser Ala Leu Gly Ser 
260 265 270 
Arg Glu Leu Ile Ser Ala Val Glu Ala Asn Asn Met Lys Arg Thr Ala 
275 280 285 
Tyr Asp Val Arg Ala Ser Ala Ala Ile Ala Tyr Gly Asp Pro Tyr Val 
290 295 300 
Tyr Ala Val Gin Pro Gly Met Val Ala Glu Lys Leu Arg Asn Gly Pro 
305 310 315 320 
Asp Ile Ile Leu Ala Asp His Ala Leu Thr Glu Asp Ala Leu Ala Ile 
325 330 335 
His Met Ser Ala Val Val Arg Leu Ile Thr Asp Gly Asp Leu Asn Asp 
340 345 350 
Gly Gly Gly Ala Leu Asp Ala Ala Lys Ala Lys Leu Ser Glu Ser Ala 
355 360 365 
Arg Arg Ala Trp Gly Ala Val Gin His Ser Ser Ser Pro Arg Gin Leu 
370 375 380 
Leu Glu Ala Leu Ile Glu Arg Gly Phe Val Arg Gin Ala Cys Arg Val 
385 390 395 400 
Tyr Glu Ser Ala Leu Lys Ala Asn Leu Gly Lys Thr Arg Gly Thr Val 
405 410 415 
Asn Glu Leu Asp Thr Phe Asp Asp Val Gin Gin Val Ile Gly Asn Ile 
420 425 430 
Val Phe Gly Leu Met Glu Ser Tyr Gly Pro Gly Met Thr Tyr Leu Thr 
435 440 445 
Asn Tyr Met Asp Asn Gly Leu Pro Pro Asp Ala Asp Ser Asp Phe Ile 
450 455 460 
Lys Val Leu Gly Leu Asp Ser Ala Ile Ile Ala Gln Ile Leu Gly Arg 
465 470 475 480 
Cys Ile Pro Pro Asn Pro His Glu Asp Tyr Val Lys Ser Ala Arg Ala 
485 490 495 
Ile Leu Ala Ala Glu Met Asp Ser Ala Ile Arg Gin Ser Gly Ala Gly 
500 505 510 
Thr Ala Asn Arg Ala Ile Gin Phe Ala Lys Glu Ser Leu Met Leu Trp 
515 520 525 
Phe Asp Ser Arg Ala Glu His Ile Trp Gly Ile 
530 535 
< 210 > SEQ ID NO 30 
< 211 > LENGTH : 544 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 30 
Met Ser Ala Leu Gly Lys Gly Asp Asn Tyr Pro Leu Asn Ala Leu Leu 
1 5 10 15 
Asp Thr Leu Gln Thr Leu Cys Ala Glu Asn Ser Pro Thr Glu Pro Trp 
20 25 30 
Pro Val Thr Val Ile Ser Glu Ala Arg Ala Ala Ile Gly Thr Phe Phe 
35 40 45 
Leu Ser Ser Thr Gin Met Ser Ile Gin Gin Val Glu Ser Thr Trp Arg 
50 55 60 
Asp Val Phe Ser Val Ile Leu Glu Val Tyr Gin Arg Thr Lys Ser Pro 
70 75 80 65 
Glu Ala Ala Met Leu Ala Gln Asn Phe Thr Gly Leu Ile Leu Trp Arg 
85 90 95 
US 10,647,964 B2 
65 66 
- continued 
Val Ser Val Arg Trp Asp Lys Thr Ser Trp Arg Asp Glu Ser Ile Arg 
100 105 110 
Leu Arg Lys Leu Val Gly Glu Met Thr Gly Glu Glu Pro Ile Thr Trp 
115 120 125 
Leu Ser Arg Asn Asn Leu Arg Val Ser Ala Ser Phe Gly Pro Asn Val 
130 135 140 
Met Gly Pro Leu Ile Thr Asp Trp Phe Ala Glu Phe Glu Asp Thr Val 
145 150 155 160 
Thr Ser Ala Val Ser Tyr Thr Pro Glu Cys Leu Leu Ser Glu Arg Glu 
165 170 175 
Arg Ile Pro Asn Val Trp Asn Leu Thr Asp Ser Leu Ala His Lys Arg 
180 185 190 
Phe Glu Leu Ile Tyr Asp Phe Pro Phe Val Gin Glu Gly Ile Arg Leu 
195 200 205 
Ile Ala Arg Thr Val Gly Trp Val Val Pro Phe Val Ile Leu Tyr Arg 
210 215 220 
Cys Thr Thr Asn Arg Ala Phe Thr Pro Leu Thr Arg Ile Leu Phe Thr 
225 230 235 240 
Ile Ala Phe Ile Asp Gin Tyr Phe Arg Gly Lys Gly Ala Ser Gin His 
245 250 255 
Ser Val Leu Lys Glu Arg Phe Ala Glu Asp Cys Asn Ala Leu Gly Ser 
260 265 270 
Glu Glu Leu Met Ser Ala Ser Gin Ala Asn Leu Thr Lys Arg Thr Ser 
275 280 285 
Tyr Glu Val Arg Ala Ser Ala Ala Ile Ala Tyr Gly Asp Pro Phe Ile 
290 295 300 
Tyr Gly Ile Gln Pro Gly Met Val Ala Glu Arg Leu Arg Ser Gly Glu 
305 310 315 320 
Asp Ile Ile Val Ser Ser Thr Ser Leu Thr Glu Asp Ser Leu Ala Ile 
325 330 335 
His Ile Ser Ala Val Leu Gin Leu Ile Ser Ser Asp Gly Ser Asp His 
340 345 350 
Ser Thr Ser Val Ile Asp Glu Ala Arg Thr Lys Leu Ser Glu Ser Val 
355 360 365 
Arg Arg Ala Trp Asp Ala Ile Gin Tyr Ser Ser Ser Pro Lys Gin Leu 
370 375 380 
Leu Glu Ala Leu Ile Asp Asn Gly Phe Val Arg Gin Ser Cys Gin Ala 
385 390 395 400 
Tyr Glu Ser Ala Leu Lys Thr Tyr Met Ala Lys Asn Tyr Arg Asn Ser 
405 410 415 
Val Glu Thr Ile Phe Asn Asp Leu Gin Gin Val Ile Gly Cys Val Ala 
420 425 430 
Val Ile Gly Asn Ile Val Phe Gly Leu Ile Glu Ser Tyr Gly Pro Gly 
435 440 445 
Met Asn Tyr Leu Glu Asn Tyr Val Asp Gly Ser Leu Pro Pro Glu Ser 
450 455 460 
Asp Ser Glu Phe Ile Phe Ala Leu Gly Leu Glu His Gly Leu Ile Ser 
465 470 475 480 
Gin Ile Leu Gly Arg Cys Ile Pro Pro Asp Thr His Asp Asp Tyr Val 
485 490 495 
Lys Thr Thr Arg Ser Val Leu Leu Ala Glu Met Asp Leu Ile Ala Arg 
500 505 510 
US 10,647,964 B2 
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- continued 
Lys Met Asp Val Gly Gly Ser Ala Arg Ala Leu Ser Ser Ala Arg Glu 
515 520 525 
Ser Leu Leu Leu Trp Phe Asp His Arg Ala Glu Val Ile Trp Gly Leu 
530 535 540 
< 210 > SEQ ID NO 31 
< 211 > LENGTH : 573 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 31 
Met Asp Ser Gly Asp Gin Leu Ser Asp Asn Glu Tyr Tyr Asp Leu Asp 
1 5 10 15 
Glu Asp Asn Thr Cys Ser Asp Asn Arg Ser Pro Arg Pro Val Gly Arg 
20 25 30 
Trp Leu Leu Lys Asp Met Ile Val Ala Leu Lys Glu Ile Ile Asn Thr 
35 40 45 
Gin Ser Thr Pro Arg Trp Thr Glu Val Glu Ala Ser Lys Val Lys Ala 
50 55 60 
Ile Val Ser Thr Phe Cys Leu Ser Gin Glu Gln Met Thr Ile Pro Gin 
65 70 75 80 
Ile Ser His Ser Trp Lys Glu Ala Phe Asp Leu Leu Leu Val Ala Phe 
85 90 95 
Ser Asn Thr Gln Thr Pro Glu Val Ala Ile Ile Ile Glu Asn Phe Thr 
100 105 110 
Gly Leu Val Ile Trp Arg Leu Val Val Ser Trp Asp Arg Asn Thr Val 
115 120 125 
Lys Ala Asp Val Thr Lys Leu Met Ala Leu Val Arg Asp Leu Thr Ser 
130 135 140 
Glu His Val Thr Gin Ser Leu Thr Arg Gin Asn Leu Arg Leu Ser Thr 
145 150 155 160 
Ser Tyr Gly Val Ser Ala Met Arg Gly Ile Leu Leu Ser Trp Leu Thr 
165 170 175 
Thr Phe Glu Ala Ala Val Thr Thr Val Leu Ala Thr Thr Pro Asp Val 
180 185 190 
Phe Leu Leu Asp Ser Glu Arg Leu Gly Phe Arg Lys Asp Arg Val Pro 
195 200 205 
Thr Ser Arg Tyr Ile Arg Ile Ile Tyr Asp Phe Pro Phe Val Gln Glu 
210 215 220 
Gly Leu Arg Phe Leu His Arg Asn Ala Asn Trp Met Ile Pro Phe Lys 
225 230 235 240 
Ile Met Thr Arg Cys Ala Ser Asp Thr Ile Tyr Ser Pro Leu Val Arg 
245 250 255 
Thr Ile Tyr Thr Ile Ser Leu Val Asp Gin Tyr Phe Trp Gly Ala Gly 
260 265 270 
Arg Ser Arg Pro Lys Arg Leu Val Asp Gln Phe Val Lys Asp Thr Asp 
275 280 285 
Leu Leu Gly Asp Ala Glu Leu Met Ser Pro Gly Glu Ala Asn Ser Thr 
290 295 300 
Lys Arg Thr Ser Trp Glu Val Arg Leu Ser Ala Ala Leu Ala Tyr Gln 
305 310 315 320 
Asp Pro Phe Val Arg Glu Val Gin Pro Gly Met Ala Ser Val Arg Val 
325 330 335 
Arg Thr Ser Pro Asp Met Val Leu Arg Gly Gly Pro Val Phe Gly Pro 
340 345 350 
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- continued 
Ala Leu Cys Ile His Ser Ala Ala Val Leu Asn Val Ile Ser Gly Ser 
355 360 365 
Lys Gln Asp Glu Phe Asp Leu Gly Arg Leu Asn Gln Ala Ala Lys Thr 
370 375 380 
Thr Ile Thr Glu Ala Ala Arg Ala Ala Trp Asp Thr Ile Gin His Ser 
385 390 395 400 
Asn Thr Pro Gin Gin Val Ile Asp Ala Leu Ile Ser Thr Gly Phe Val 
405 410 415 
Ala Gln Asn Cys Arg Asn Tyr Glu Val Ala Leu Thr Ser Met Tyr Ser 
420 425 430 
Arg Ala Thr Thr Asp Asn Gly Tyr Ala Leu Asn Asp Thr Gin Gin Val 
435 440 445 
Ile Gly Cys Val Ser Met Val Gly Asn Val Val Phe Gly Leu Ile Asp 
450 455 460 
Ser Tyr Gly Arg Asp Ala Asp Tyr Ile Asp Ala Tyr Ala Glu Ala Met 
465 470 475 480 
Ser Ser Leu Glu Ser Asp Ser Gly Asp Phe Leu Ser Ala Ile Gly Leu 
485 490 495 
Pro Lys Gly Gly Ile Glu Gin Thr Ile Arg His Cys Met Ala Pro Arg 
500 505 510 
Pro Ile Thr Asp Tyr Ile Arg Ala Ala Arg Gin Ala Leu Val Gln Glu 
515 520 525 
Ile Glu Thr Ala Ser Ser Ile Tyr Lys Gly Arg Leu Ser Ser Arg Leu 
530 535 540 
Gin Thr His His Thr Ser Thr His Asn Ser Val Arg Gly Ser Leu Leu 
545 550 555 560 
Leu Trp Phe Asp Phe Arg Ala Lys Gln Ile Trp Gly Ile 
565 570 
< 210 > SEQ ID NO 32 
< 211 > LENGTH : 636 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 32 
Met Val Ser Pro Thr Pro Thr Pro Pro Pro Lys Glu Gly Arg Ala Ala 
1 5 10 15 
Thr Pro Pro Lys Glu Gly Arg Ala Ala Thr Pro Pro Arg Asp Asp Arg 
20 25 30 
Ala Pro Pro Val Pro Lys Asp Asn Thr Ala Ala Thr Pro Ser Asp Asn 
35 40 45 
Ala Arg Thr Thr Pro Ser Thr Lys Glu Asp Gly Ala Ala Ala Pro Pro 
50 55 60 
65 
Pro Ala Ala Pro Pro Gly Asp Gly Arg Ala Pro Ser Pro Ser Gly Asn 
75 80 70 
Ser Arg Pro Gly His Pro Thr Asp Gly Pro Leu Gin Ser Leu Leu Gly 
85 90 95 
Ala Leu Ala Ser Leu Ala Ala Ala Gly Pro Ala Ser Pro Ala Glu Thr 
100 105 110 
Pro Arg Asp Ala Asp Glu Asp Ser Val Leu Leu Ala Ala Lys Leu Arg 
115 120 125 
Ala Ala Ile Ala Ala Phe Leu Leu Ser Thr Ala Pro Ile Arg Val Val 
130 135 140 
Asp Ala Arg Thr His Trp Arg Pro Leu Leu Glu Arg Leu Cys Asp Leu 
US 10,647,964 B2 
71 72 
- continued 
145 150 155 160 
His Gly Ala His Gly Leu Pro Glu Thr Ala Leu Leu Ala Glu Asn Leu 
165 170 175 
Pro Gly Leu Leu Ala His Arg Leu Ala Val Ala Leu Pro Asp Asp Pro 
180 185 190 
Glu Arg Ala Phe Glu Ala Met Asp Asp Leu Lys Ala Gly Val Leu Ala 
195 200 205 
Thr Thr Ser Pro Glu Ala Thr Arg Leu Leu Glu Ala Ala Gly Leu Arg 
210 215 220 
Thr Ala Ala Ala Leu Gly Pro Ala Arg Thr Arg Gin Cys Val Thr Glu 
225 230 235 240 
Trp Thr Asp Arg Trp Arg Ser Val Ser Glu Ser Cys Leu Arg Leu Asp 
245 250 255 
Pro Arg Ala Ala Ser Gly Ala Pro Ala Asp Ala Ser Pro Pro Val Ser 
260 265 270 
Pro Ile Pro Leu Gly Gin Pro Gly Ala Gly Leu Thr Thr Pro Ala Tyr 
275 280 285 
Ser Thr Ile Phe Pro Ala Pro Phe Val Gln Glu Gly Leu Arg Phe Leu 
290 295 300 
Ala Arg Ala Ser Asn 
305 
Trp Ala Thr Leu Phe Ser Thr His Leu Gin Arg 
310 315 320 
Val Asp Asp Ala Thr Leu Thr Pro Leu Thr Arg Ala Leu Phe Thr Leu 
325 330 335 
Ala Leu Val Asp Glu Tyr Leu Thr Thr Arg Asp Arg Gly Ile Val Ala 
340 345 350 
Pro Pro Arg Leu Leu Glu Gln Phe Glu His Thr Val Arg Glu Ile Asp 
355 360 365 
Pro Ala Ile Met Ile Pro Pro Ile Glu Ala Asn Lys Met Val Arg Thr 
370 375 380 
Arg Glu Glu Val Arg Val Ser Ala Ala Leu Asn His Leu Thr Pro Arg 
385 390 395 400 
Ser Ala Arg Ala Pro Pro Gly Thr Leu Met Thr Arg Val Arg Thr Asp 
405 410 415 
Ala Ala Val Phe Asp Pro Glu Glu Pro Leu Leu Ser Ser Ser Ala Leu 
420 425 430 
Ala Ile Phe Gin Pro Ala Val Ala Ala Leu Leu Gly Ser Gly Glu Pro 
435 440 445 
Pro Ser Ala Gly Ala Gin Arg Arg Leu Leu Ala Leu Leu His Gin Thr 
450 455 460 
Trp Ala Leu Ile Gin Asn Thr Gly Ser Pro Ser Val Val Ile Asn Ala 
465 470 475 480 
Leu Ile Asp Ala Gly Phe Thr Pro Leu His Cys Ser His Tyr Leu Ser 
485 490 495 
Ala Leu Glu Gly Phe Leu Ala Thr Gly Gly Ala Ser Arg Gly Leu Ala 
500 505 510 
Gly Pro Gly Leu Ser Glu Ile Gin Gin Leu Phe Gly Cys Ile Ala Leu 
515 520 525 
Thr Gly Ala Asn Val Phe Ala Leu Ala Arg Glu Tyr Gly Tyr His Ser 
530 535 540 
Gly Tyr Val Arg Ala Phe Arg Arg Ile Gin Asp Ala Cys Glu Lys Ala 
545 550 555 560 
His Ala Arg Leu Cys Glu Ala Ala Gly Leu Thr Gly Gly Val Leu Ser 
565 570 575 
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- continued 
Gin Thr Leu Ala Arg Val Met Gly Pro Val Thr Pro Thr Glu His Leu 
580 585 590 
Ala Ser Leu Arg Arg Ala Leu Val Gly Glu Phe Glu Ser Ala Glu Arg 
595 600 605 
Arg Phe Gly Ala Gly Arg Ala Ser Pro Leu Arg Glu Thr Val Leu Ile 
610 615 620 
Trp Val Asp Val Tyr Gly Gin Thr Glu Trp Asp Ile 
625 630 635 
< 210 > SEQ ID NO 33 
< 211 > LENGTH : 655 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 33 
Met Val Ser Pro Thr Pro Thr Pro Pro Thr Glu Glu Asn Arg Ser Arg 
1 5 10 15 
Pro Ala Pro Pro Pro Lys Glu Ala Arg Gly Ser Ala Ala Thr Ser Pro 
20 25 30 
Lys Glu Thr Arg Ser Arg Thr Thr Pro Pro Pro Lys Glu Ala Arg Gly 
35 40 45 
Ser Ala Ala Thr Ser Pro Glu Asn Val Arg Thr Ala Pro Ala Pro Gly 
50 55 60 
Asp Thr Arg Ala Ala Ala Pro Pro Thr Pro Glu Glu Thr Arg Ala Pro 
65 70 75 80 
Pro Pro Pro Ala Thr Pro Pro Glu Asp Val Arg Ala Ala Thr Pro Ser 
85 90 95 
Gly Asp Ala Arg Leu Gly Pro Pro Pro Asp Gly Pro Leu Gin Ser Leu 
100 105 110 
Leu Gly Ala Leu Thr Ser Leu Ala Thr Ala Arg Pro Ala Pro Pro Thr 
115 120 125 
Glu Ala Ser Gly Glu Ala Gly Glu Asp Ala Val Leu Leu Ala Ala Arg 
130 135 140 
Leu Arg Ala Ala Ile Ala Ala Phe Leu Leu Ser Gly Ala Pro Ile Arg 
145 150 155 160 
Val Ala Asp Ala Arg Thr His Trp Arg Pro Leu Leu Glu Arg Leu Cys 
165 170 175 
Ala Leu His Gly Ala His Gly Leu Pro Glu Thr Ala Leu Leu Ala Glu 
180 185 190 
Asn Leu Pro Gly Leu Leu Ala His Arg Leu Ala Val Ala Leu Pro Asp 
195 200 205 
Ala Pro Asp Arg Ala Phe Glu Ala Met Asp His Leu Arg Ala Ala Val 
210 215 220 
Leu Asp Ala Ala Ser Pro Glu Ala Thr Arg Leu Leu Glu Ala Ala Gly 
225 230 235 240 
Leu Arg Thr Ala Ala Ala Leu Gly Pro Ala Arg Thr Arg Gin Cys Val 
245 250 255 
Ala Glu Trp Thr Asp Arg Trp Arg Ser Val Thr Glu Ser Cys Leu Arg 
260 265 270 
Leu Asp Pro Arg Ala Ser Ser Ala Ala Pro Gly Gly Ala Asp Pro Pro 
275 280 285 
Val Ser Pro Val Pro Leu Gly Gin Pro Ser Ala Gly Leu Ala Thr Pro 
290 295 300 
Ala Tyr Ser Pro Ile Phe Pro Ala Pro Phe Val Gin Glu Gly Leu Arg 
US 10,647,964 B2 
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- continued 
305 310 315 320 
Phe Leu Ala Arg Ala Ser Asn Trp Ala Thr Leu Phe Ser Thr His Leu 
325 330 335 
Gin Ser Val Asp Asp Ala Thr Leu Thr Pro Leu Thr Arg Ala Leu Phe 
340 345 350 
Thr Leu Ser Leu Val Asp Glu Tyr Leu Thr Thr Arg Asp Arg Gly Ile 
355 360 365 
Val Ala Pro Pro Arg Leu Leu Glu Gin Phe Glu Arg Thr Val Arg Glu 
370 375 380 
Ile Asp Pro Ala Ile Met Ile Pro Pro Ile Glu Ala Asn Lys Met Val 
385 390 395 400 
Arg Ser Arg Glu Glu Val Arg Val Ser Ala Ala Leu Asn His Leu Thr 
405 410 415 
Pro Arg Ser Ala Arg Ala Pro Pro Gly Thr Leu Met Ser Arg Val Arg 
420 425 430 
Thr Asp Ala Ala Val Phe Asp Pro Glu Glu Pro Phe Leu Ser Ala Ser 
435 440 445 
Ala Leu Ala Ile Phe Gin Pro Ala Val Ala Ala Leu Leu Gly Ser Gly 
450 455 460 
Glu Pro Pro Ser Ala Gly Ala Gln Arg Arg Leu Leu Ala Leu Leu His 
465 470 475 480 
Gin Thr Trp Ala Leu Ile Gin Asn Thr Gly Ser Pro Ser Val Val Ile 
485 490 495 
Asn Ala Leu Ile Asp Ala Gly Phe Thr Pro Leu His Cys Ser His Tyr 
500 505 510 
Leu Ser Ala Leu Glu Gly Phe Leu Ala Ala Gly Gly Ala Ala Arg Gly 
515 520 525 
Leu Ala Gly Pro Pro Ala Leu Ser Glu Val Gin Gin Leu Phe Gly Cys 
530 535 540 
Val Ala Leu Thr Gly Ala Asn Val Phe Ala Leu Ala Arg Glu Tyr Gly 
545 550 555 560 
Tyr His Ser Gly Tyr Val Arg Ala Phe Arg Arg Val Gin Asp Ala Cys 
565 570 575 
Glu Gin Ala is Ala Arg Leu Cys Glu Ala Ala Gly Leu Ala Gly Gly 
580 585 590 
Val Leu Ser Gin Thr Leu Ala Arg Val Met Gly Pro Val Thr Pro Thr 
595 600 605 
Glu His Leu Ala Ser Leu Arg Arg Ala Leu Val Gly Glu Phe Glu Ser 
610 615 620 
Ala Glu Arg Arg Phe Gly Ala Gly Arg Pro Ser Pro Leu Arg Glu Thr 
625 630 635 640 
Val Leu Ile Trp Ile Asp Val Tyr Gly Gin Thr Glu Trp Asp Ile 
645 650 655 
< 210 > SEQ ID NO 34 
< 211 > LENGTH : 570 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 34 
Met Ser Asp Ser Ala Leu Gin Val Pro Ala Pro Ala Gly Met Thr Pro 
1 5 10 15 
Pro Ser Ala Pro Pro Pro Asn Gly Pro Leu Gln Val Leu Leu Gly Ser 
20 25 30 
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- continued 
Leu Thr Asn Leu Arg Arg Pro Pro Ser Pro Ser Ser Glu Pro Ala Gly 
35 40 45 
Ser Ala Asp Glu Pro Ala Phe Leu Ser Ala Ala Lys Leu His Ala Ala 
50 55 60 
Thr Ala Ala Phe Leu Leu Ser Gly Ala Ala Val Gly Pro Ala Glu Ala 
65 70 75 80 
Arg Ala Cys Trp His Pro Leu Leu Glu Gin Leu Cys Ala Leu His Arg 
85 90 95 
Ala His Gly Leu Pro Glu Thr Ala Leu Leu Ala Glu Asn Leu Pro Gly 
100 105 110 
Leu Leu Val His Arg Met Ala Val Ala Leu Pro Glu Thr Pro Glu Ala 
115 120 125 
Ala Phe Arg Glu Met Asp Val Ile Lys Asp Thr Val Leu Ala Ile Thr 
130 135 140 
Gly Ser Asp Thr Thr His Ala Leu Glu Ala Ala Gly Leu Arg Thr Thr 
145 150 155 160 
Ala Ala Leu Gly Pro Val Arg Val Arg Gln Cys Ala Val Glu Trp Ile 
165 170 175 
Asp Arg Trp Arg Thr Val Thr Gin Ser Cys Leu Ala Met Asn Pro Arg 
180 185 190 
Thr Ser Leu Glu Ala Leu Gly Glu Met Ser Leu Lys Met Ser Pro Val 
195 200 205 
Pro Leu Gly Gin Pro Gly Ala Asn Leu Thr Thr Pro Ala Tyr Ser Leu 
210 215 220 
Leu Phe Pro Ser Pro Ile Val Gin Glu Gly Leu Arg Phe Leu Ala Leu 
225 230 235 240 
Val Ser Asn Trp Val Thr Leu Phe Ser Ala His Leu Gin Arg Ile Asp 
245 250 255 
Asp Ala Ala Leu Thr Pro Leu Thr Arg Ala Leu Phe Thr Leu Ala Leu 
260 265 270 
Val Asp Asp Tyr Leu Thr Thr Pro Asp Arg Gly Ala Val Val Pro Pro 
275 280 285 
Pro Leu Leu Ala Gin Phe Gin His Thr Val Arg Glu Ile Asp Pro Ala 
290 295 300 
Ile Met Ile Pro Pro Leu Glu Ala Thr Lys Met Val Arg Ser Arg Glu 
305 310 315 320 
Glu Val Arg Val Ser Thr Ala Leu Ser Arg Val Ser Pro Arg Ser Ala 
325 330 335 
Cys Ala Pro Pro Gly Thr Leu Met Ala Arg Val Arg Thr Asp Ala Ala 
340 345 350 
Val Phe Asp Pro Asp Val Pro Phe Leu Ser Ala Ser Ala Leu Ala Ile 
355 360 365 
Phe Arg Pro Ala Val Thr Gly Leu Leu Gin Leu Gly Glu Pro Pro Ser 
370 375 380 
Ala Gly Ala Gin Gin Arg Leu Leu Ala Leu Leu Gin Gin Thr Trp Ala 
385 390 395 400 
Leu Val Gin Asn Ser Asn Ser Pro Ser Val Val Ile Asn Thr Leu Thr 
405 410 415 
Asp Ala Gly Phe Thr Pro Ala His Cys Thr Gln Tyr Ile Ser Ala Leu 
420 425 430 
Glu Gly Phe Leu Val Ala Gly Val Pro Ala Arg Thr Pro Pro Gly His 
435 440 445 
Gly Leu Ser Glu Ile Gin Gin Leu Phe Gly Cys Ile Ala Leu Ala Gly 
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- continued 
450 455 460 
Ala Asn Val Phe Gly Leu Ala Arg Glu Tyr Gly His Tyr Ala Gly Tyr 
465 470 475 480 
Val Lys Thr Phe Arg Arg Ile Gln Gly Ala Ser Glu His Thr His Gly 
485 490 495 
Arg Leu Cys Glu Ala Val Gly Leu Ser Gly Gly Val Leu Ser Gin Thr 
500 505 510 
Leu Ala Arg Ile Met Gly Pro Ala Val Pro Thr Glu His Leu Ala Ser 
515 520 525 
Leu Arg Arg Thr Leu Val Gly Glu Phe Glu Thr Ala Glu Arg Arg Phe 
530 535 540 
Ser Ala Gly Gln Pro Ser Leu Leu Arg Glu Thr Ala Leu Ile Trp Leu 
545 550 555 560 
Asp Val Tyr Gly Gin Thr His Trp Asp Leu 
565 570 
< 210 > SEQ ID NO 35 
< 211 > LENGTH : 570 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpes virus 
< 400 > SEQUENCE : 35 
Met Ala Asp Arg Gly Leu Pro Ser Glu Ala Pro Val Val Thr Thr Ser 
1 5 10 15 
Pro Ala Gly Pro Pro Ser Asp Gly Pro Met Gln Arg Leu Leu Ala Ser 
20 25 30 
Leu Ala Gly Leu Arg Gin Pro Pro Thr Pro Thr Ala Glu Thr Ala Asn 
35 40 45 
Gly Ala Asp Asp Pro Ala Phe Leu Ala Thr Ala Lys Leu Arg Ala Ala 
50 55 60 
Met Ala Ala Phe Leu Leu Ser Gly Thr Ala Ile Ala Pro Ala Asp Ala 
65 70 75 80 
Arg Asp Cys Trp Arg Pro Leu Leu Glu His Leu Cys Ala Leu His Arg 
85 95 90 
Ala His Gly Leu Pro Glu Thr Ala Leu Leu Ala Glu Asn Leu Pro Gly 
100 105 110 
Leu Leu Val His Arg Leu Val Val Ala Leu Pro Glu Ala Pro Asp Gln 
115 120 125 
Ala Phe Arg Glu Met Glu Val Ile Lys Asp Thr Ile Leu Ala Val Thr 
130 135 140 
Gly Ser Asp Thr Ser His Ala Leu Asp Ser Ala Gly Leu Arg Thr Ala 
145 150 155 160 
Ala Ala Leu Gly Pro Val Arg Val Arg Gin Cys Ala Val Glu Trp Ile 
165 170 175 
Asp Arg Trp Gln Thr Val Thr Lys Ser Cys Leu Ala Met Ser Pro Arg 
180 185 190 
Thr Ser Ile Glu Ala Leu Gly Glu Thr Ser Leu Lys Met Ala Pro Val 
195 200 205 
Pro Leu Gly Gin Pro Ser Ala Asn Leu Thr Thr Pro Ala Tyr Ser Leu 
210 215 220 
Leu Phe Pro Ala Pro Phe Val Gin Glu Gly Leu Arg Phe Leu Ala Leu 
225 230 235 240 
Val Ser Asn Arg Val Thr Leu Phe Ser Ala His Leu Gin Arg Ile Asp 
245 250 255 
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Asp Ala Thr Leu Thr Pro Leu Thr Arg Ala Leu Phe Thr Leu Ala Leu 
260 265 270 
Val Asp Glu Tyr Leu Thr Thr Pro Glu Arg Gly Ala Val Val Pro Pro 
275 280 285 
Pro Leu Leu Ala Gin Phe Gln His Thr Val Arg Glu Ile Asp Pro Ala 
290 295 300 
Ile Met Ile Pro Pro Leu Glu Ala Asn Lys Met Val Arg Ser Arg Glu 
305 310 315 320 
Glu Val Arg Val Ser Thr Ala Leu Ser Arg Val Ser Pro Arg Ser Ala 
325 330 335 
Cys Ala Pro Pro Gly Thr Leu Met Ala Arg Val Arg Thr Asp Val Ala 
340 345 350 
Val Phe Asp Pro Asp Val Pro Phe Leu Ser Ser Ser Ala Leu Ala Val 
355 360 365 
Phe Gin Pro Ala Val Ser Ser Leu Leu Gln Leu Gly Glu Gin Pro Ser 
370 375 380 
Ala Gly Ala Gin Gin Arg Leu Leu Ala Leu Leu Gin Gin Thr Trp Thr 
385 390 395 400 
Leu Ile Gln Asn Thr Asn Ser Pro Ser Val Val Ile Asn Thr Leu Ile 
405 410 415 
Asp Ala Gly Phe Thr Pro Ser His Cys Thr His Tyr Leu Ser Ala Leu 
420 425 430 
Glu Gly Phe Leu Ala Ala Gly Val Pro Ala Arg Thr Pro Thr Gly His 
435 440 445 
Gly Leu Gly Glu Val Gin Gin Leu Phe Gly Cys Ile Ala Leu Ala Gly 
450 455 460 
Ser Asn Val Phe Gly Leu Ala Arg Glu Tyr Gly Tyr Tyr Ala Asn Tyr 
465 470 475 480 
Val Lys Thr Phe Arg Arg Val Gin Gly Ala Ser Glu His Thr His Gly 
485 490 495 
Arg Leu Cys Glu Ala Val Gly Leu Ser Gly Gly Val Leu Ser Gin Thr 
500 505 510 
Leu Ala Arg Ile Met Gly Pro Ala Val Pro Thr Glu His Leu Ala Ser 
515 520 525 
Leu Arg Arg Ala Leu Val Gly Glu Phe Glu Thr Ala Glu Arg Arg Phe 
530 535 540 
Ser Ser Gly Gln Pro Ser Leu Leu Arg Glu Thr Ala Leu Ile Trp Ile 
545 550 555 560 
Asp Val Tyr Gly Gin Thr His Trp Asp Ile 
565 570 
< 210 > SEQ ID NO 36 
< 211 > LENGTH : 612 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Herpesvirus saimiri 
< 400 > SEQUENCE : 36 
Met Thr Gln Ala Thr Arg Thr Arg Val Pro Val Glu Trp His Glu Leu 
1 5 10 15 
Ile Ala Ala Ala Glu Asn Asp Leu Arg Glu His Ala Pro Ala Pro Ser 
20 25 30 
His Val Gly Ser Ile Trp Asn Leu Val Asp Thr Leu Glu Pro Leu Ala 
35 40 45 
Thr Gln Leu Arg Glu Met Ser Arg Ala Ala Thr Ala Ala Ala Pro Pro 
50 55 60 
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- continued 
Arg Leu Ser Pro Gly Ala Ala Gly Arg Lys Leu Val Gly His Gly Ser 
65 70 75 80 
Ala Tyr Pro Pro Glu Gin Thr Phe Leu Leu Val Ala Arg Leu Arg Ala 
85 90 95 
Ala Phe Ala Ser Phe Leu Leu Ala Pro Thr Ala Ala Ala Pro Glu His 
100 105 110 
Val Arg Ser Gly Trp Pro Arg Leu Ile Ser Leu Leu Cys Glu Leu His 
115 120 125 
Arg Gly Leu Ser Leu Thr Glu Thr Ala Leu Leu Leu Glu Asn Leu Pro 
130 135 140 
Gly Leu Ala Val His His Ile Asp Val Ala Val Pro Arg Asp Arg Ala 
145 150 155 160 
Gly Ala Cys Arg Asp Met Ser Ala Val Ile Ala Cys Val Arg Lys Met 
165 170 175 
Ala Gly Pro Glu Thr Val Asp Ala Leu Glu Glu Leu Gly Leu Arg Thr 
180 185 190 
Ser Ser Pro Leu Gly Pro Ile Ser Thr Gin Arg Asn Val Leu Asp Trp 
195 200 205 
Val Gln Arg Trp Leu Ala Val Thr Lys Ser Met His Glu Ala Asp Pro 
210 215 220 
Arg Glu Ser Ala Asp Phe Ser Ser Ala Pro Pro Leu Lys Asn Leu Ala 
225 230 235 240 
Thr Leu Pro Leu Gly Gin Pro Gly Ala Gly Leu Ala Ala Pro Lys Tyr 
245 250 255 
His Leu Ile Phe Gly Ala Pro Phe Val Gln Arg Gly Leu Arg His Leu 
260 265 270 
Ala Glu Val Gly Asn Arg Val Cys Val Val Gly Ala Tyr Leu Arg Arg 
275 280 285 
Ala Asp Asp Ala Ala Leu Thr Pro Leu Ala Arg Ala Leu Phe Thr Leu 
290 295 300 
Ala Leu Val Asp Glu His Val Pro Ser Gly Gly Gly Val Pro Ser Leu 
305 310 315 320 
Leu Val Gln Arg Phe Arg Arg Asp Val Ala Leu Val Asp Pro Thr Ile 
325 330 335 
Met Ile Pro Pro Leu Glu Ala Asn Pro Met Pro Arg Thr Arg Gly Glu 
340 345 350 
Val Arg Ile Ser Ser Ala Leu Ser Thr Arg Thr Pro Gly Val Thr Cys 
355 360 365 
Ala Pro Pro Gly Thr Leu Ile Thr Arg Val Arg Thr Asp Ser Asp Val 
370 375 380 
Phe Gly Thr His Pro Glu His Val Ser Ala Ser Ala Leu Ala Val Phe 
385 390 395 400 
Gin Pro Ala Val Ser Ser Leu Leu Gln Ala Gly Glu Thr Glu Ala Thr 
405 410 415 
Pro Glu Val Arg Gln Arg Met Leu Gly Leu Leu His Glu Thr Trp Ala 
420 425 430 
Arg Leu Gln Asn Thr Thr Ser Ala Asp Val Ala Leu Ala Thr Leu Val 
435 440 445 
Asp Ala Gly Phe Thr Pro Ala Asn cys Ala Ala Tyr Leu Ser Ala Leu 
450 455 460 
Glu Gly Phe Leu Ala Ser Gly His Leu Val Ala Ser Ala Asp Ser Gly 
465 470 475 480 
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- continued 
Glu Lys Asp Ala Arg Gly Leu Asp Gly Arg Glu Leu Gly Glu Ile Gln 
485 490 495 
Gln Leu Phe Gly Cys Ile Ser Ile Leu Gly Arg Gly Ile Phe Gln Leu 
500 505 510 
Ala Arg Glu Tyr Gly Pro His Ala Glu Tyr Val Lys Thr Phe Lys Arg 
515 520 525 
Ile Gin Ala Ala Cys Glu Gin Arg His Ala Gin Leu Ser His Ala Ala 
530 535 540 
Gly Leu Ser Gin Gly Val Leu Gly Gin Ala Leu Ala Arg Ile Met Ser 
545 550 555 560 
Pro Thr Thr Pro Thr Glu His Leu Ala Ala Leu Arg Arg Ala Leu Val 
565 570 575 
Asp Glu Phe Glu Val Ala Glu Arg Arg Phe Asn Glu Gly His Pro Ser 
580 585 590 
Leu Leu Arg Glu Pro Val Met Ala Trp Val Asp Ile Tyr Gly Gin Thr 
595 600 605 




We claim : 8. The virus particle of claim 6 , wherein said virus is 
1. A variant herpesvirus or alphaherpes virus particle avirulent . 
comprising at least two mutations in a UL37 protein selected 9. A nucleic acid encoding the virus particle of claim 1 . 
from the group consisting if SEQ ID NO : 34 , SEQ ID NO : 10. A vector comprising the nucleic acid of claim 9 . 
35 , a sequence having at least 90 % sequence identity to SEQ 11. A pharmaceutical composition comprising the virus 
ID NO : 34 and a sequence having at least 90 % sequence particle , a nucleic acid encoding the virus particle , or a vector comprising the nucleic acid encoding the virus par identity to SEQ ID NO : 35 , wherein the mutations are at a ticle of claim 1 and a pharmaceutically acceptable carrier . 
position selected from the group consisting of Q403 , E452 , 12. A vaccine composition comprising the virus particle , 
Q455 , Q511 , and R515 , wherein said virus particle exhibits 35 a nucleic acid encoding the virus particle , or a vector 
reduced neuro - invasiveness relative to a virus particle lack comprising the nucleic acid encoding the virus particle of 
ing said mutation , and wherein the ability of the virus to claim 1 and a pharmaceutically acceptable carrier . 
replicate in peripheral tissues is retained . 13. A method of inducing an immune response against a 
2. The virus particle of claim 1 , wherein said virus is virus , comprising : administering the composition of claim 
selected from the group consisting of herpes simplex virus - 1 11 to a subject under conditions such that said subject 
( HSV - 1 ) and herpes simplex virus - 2 ( HSV - 2 ) . generates an immune response to said virus . 
3. The virus particle of claim 1 , wherein said the UL37 14. The method of claim 13 , wherein said subject is human or is a non - human animal . protein of said virus has at least 95 % sequence identify to a 
sequence selected from the group consisting of SEQ ID 15. A method of preventing infection by a virus , com prising : administering the composition of claim 11 to a NOS : 34-35 . 
4. The virus particle of claim 1 , wherein said one or more subject under conditions such that said subject generates an 
mutations is at least two or more . immune response to said virus . 16. A method of treating or preventing cancer , compris 5. The virus particle of claim 1 , wherein said one or more 
mutations is at least three or more . ing : administering the composition of claim 11 to a subject diagnosed with cancer under conditions such that the growth 6. The virus particle of claim 1 , wherein said one or more 50 
mutations is at least four or more . of said cancer is reduced by inducing an immune response to said virus . 7. The virus particle of claim 1 , wherein said one or more 
mutations is at least all five of said mutations . 
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